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Abstract
Human chorionic gonadotropin (hCG) is a glycoprotein hormone comprising 2 subunits, alpha and
beta joined non covalently. While similar in structure to luteinizing hormone (LH), hCG exists in
multiple hormonal and non-endocrine agents, rather than as a single molecule like LH and the other
glycoprotein hormones. These are regular hCG, hyperglycosylated hCG and the free beta-subunit
of hyperglycosylated hCG.
For 88 years regular hCG has been known as a promoter of corpus luteal progesterone
production, even though this function only explains 3 weeks of a full gestations production of
regular hCG. Research in recent years has explained the full gestational production by
demonstration of critical functions in trophoblast differentiation and in fetal nutrition through
myometrial spiral artery angiogenesis.
While regular hCG is made by fused villous syncytiotrophoblast cells, extravillous invasive
cytotrophoblast cells make the variant hyperglycosylated hCG. This variant is an autocrine factor,
acting on extravillous invasive cytotrophoblast cells to initiate and control invasion as occurs at
implantation of pregnancy and the establishment of hemochorial placentation, and malignancy as
occurs in invasive hydatidiform mole and choriocarcinoma. Hyperglycosylated hCG inhibits
apoptosis in extravillous invasive cytotrophoblast cells promoting cell invasion, growth and
malignancy. Other non-trophoblastic malignancies retro-differentiate and produce a
hyperglycosylated free beta-subunit of hCG (hCG free beta). This has been shown to be an
autocrine factor antagonizing apoptosis furthering cancer cell growth and malignancy.
New applications have been demonstrated for total hCG measurements and detection of the 3
hCG variants in pregnancy detection, monitoring pregnancy outcome, determining risk for Down
syndrome fetus, predicting preeclampsia, detecting pituitary hCG, detecting and managing
gestational trophoblastic diseases, diagnosing quiescent gestational trophoblastic disease,
diagnosing placental site trophoblastic tumor, managing testicular germ cell malignancies, and
monitoring other human malignancies. There are very few molecules with such wide and varying
functions as regular hCG and its variants, and very few tests with such a wide spectrum of clinical
applications as total hCG.
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Background
In 1920 Hirose showed a hormonal link between a
human placental hormone and progesterone production
by corpus luteal cells [1]. The name human chorionic
gonadotropin (hCG) was formulated for the hormone.
The promotion of progesterone production by corpus
luteal cells was assumed to be the principal function of
this hormone. Until recent years this has been assumed to
be the sole function for hCG.
The first pregnancy test, the rabbit test, was formulated
[2,3] in the 1920s. For four decades bioassays such as the
rabbit test were the only practical way to measure hCG or
detect pregnancy. In 1960 with the development of poly-
clonal antibodies came the agglutination inhibition test
[4]. Then, in 1967 with discovery of the competitive
immunoassays the hCG radioimmunoassay was devel-
oped [5-8]. This became the first rapid and sensitive test
and led to the dawn of commercial hCG tests as seen
today. hCG testing became part of the evaluation of every
pregnancy. The initial radioimmunuassays used an anti-
body to whole hCG α β dimer. The α-subunit of hCG is
identical with the α-subunit of LH. As such the initial RIA
detected both hCG and LH limiting its use for the early
detection or pregnancy. In 1973 the hCG β-subunit radio-
immunoassay was introduced, specifically detecting hCG
through its β-subunit [9]. This led to sensitive and specific
pregnancy tests, detecting pregnancy soon after missing
menses. The discovery of monoclonal antibodies in 1975
was paramount to the development of modern immuno-
metric tests [10]. Two-antibody immunometric assays for
hCG arose in the nineteen eighties, and with them came
sensitive antibody enzyme labeling and high sensitivity
fluorimetric and chemiluminescent tracers [11-14]. These
are the formats of assays used in commercial laboratories
today.
In 1970 hCG was shown to be a non-covalently linked
dimer [15]. The 1970s saw the determination of amino
acid sequence of hCG subunits (Figure 1), and the obser-
vation that hCG contained 4 N-linked and 4 O-linked oli-
gosaccharides [16,17]. The 1980s and 1990s saw the
determination of the structures of the N- and O-linked oli-
gosaccharides on hCG as produced in pregnancy and ges-
tational trophoblastic diseases (Figure 2) [18,19], it saw
the elaboration of the hCG subunit gene structures [20],
and to our understanding of the hCG/LH receptor and the
mechanisms of hCG endocrinology whereby hCG pro-
motes progesterone production [21,22].
Was this the completion of the hCG physiology, biochem-
istry and immunoassay story? In the past 10 years a revo-
Amino acid sequence of hCG α-subunit and β-subunit [16,17] Figure 1
Amino acid sequence of hCG α-subunit and β-subunit [16,17]. Digits indicated amino acid residue positions and N and 
O indicate the positions of N- and O-linked oligosaccharides.Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
Page 3 of 37
(page number not for citation purposes)
Structures of O-linked hexa- and tris-saccharide and N-linked Bi (biantennary) and Tri (triantennary) oligosaccharides attached  to regular hCG, hyperglycosylated hCG and hyperglycosylated hCG free β [18-20] Figure 2
Structures of O-linked hexa- and tris-saccharide and N-linked Bi (biantennary) and Tri (triantennary) oligosac-
charides attached to regular hCG, hyperglycosylated hCG and hyperglycosylated hCG free β [18-20]. NeuAc is 
N-acetylneuraminic acid or sialic acid, GalNAc in N-acetylgalactosamine, Gal is galactose, GlcNAc is N-acetylglucosamine, Man 
is mannose and Fuc is fucose.Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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lution has occurred with this molecule. Firstly, with the
finding that the polypeptides that make hCG do not just
make one biologically active molecule, but a group of
three biologically important molecules, regular hCG,
hyperglycosylated hCG and hyperglycosylated hCG free β-
subunit. Each of these three molecules having different
physiological functions and each having had separate
roles in the evolution of humans. We have also seen in the
last 10 years the elaboration of our understanding of pitu-
itary hCG and new data on hCG and trophoblast func-
tion. Furthermore, there has been the discovery of
numerous new applications when measuring only hyper-
glycosylated hCG and only the hyperglycosylated and reg-
ular free β-subunit. This review examines these hCG
variant molecules and how the past 10 years they have
changed the way they are viewed. How hCG is a key ele-
ment in the evolution of the human brain, and how today
we look differently at defined hCG variant assays and the
specificity of total hCG assays in general.
Occurrence
Regular hCG predominates in all normal and abnormal
pregnancies (Table 1). It is the principal hCG variant pro-
duced through the bulk period of pregnancy (Table 2), it
is present at reduced levels during spontaneous aborting
and ectopic pregnancy [14] and at double regular levels in
Down syndrome pregnancy [23,24]. Regular hCG is also
the principal molecule produced in individuals with
hydatidiform moles or pregnancies comprising solely tro-
phoblast tissue [18,25]. Regular hCG is also normally pro-
duced by the pituitary gland at the time of LH peaks and
in menopausal women [25,26].
Multiple variants of hCG have been detected in serum and
urine samples (Figure 3). A free α-subunit of hCG and a
free β-subunit of hCG (hCG free β) have been demon-
strated in pregnancy serum, cancer patient serum and
urine and cancer cell line culture fluids (Table 1) [27,28].
A terminal degradation variant of hCG β-subunit is found
in urine samples. This is β-subunit core fragment, it com-
prises two fragment of β-subunit,  β6–40 and β55–92,
held together by disulfide bonds (Figure 3) [29]. Urine β-
core fragment is used as a general tumor marker for all
non-gestational malignancies [30-34]. A large form of
hCG dimer is synthesized by choriocarcinoma cells
[15,18,35]. This is hyperglycosylated hCG with 1.5 fold
larger N-linked and double size O-linked oligosaccharides
(Figure 3) [18,19,36]. Similar unduly large N- and O-
linked oligosaccharides have been demonstrated on the
hCG free β produced by non-gestational cancer cells, we
call this molecule hyperglycosylated hCG free β [20,35],
Similar large oligosaccharides are found on the α-subunit
secreted in pregnancy, free α-subunit [37]. Just as hCG is
hyperglycosylated in choriocarcinoma and gets larger oli-
gosaccharide side chains, free α-subunit is further glyco-
sylated in the malignancy, gaining an additional O-linked
oligosaccharide, we call this molecule O-glycosylated free
α-subunit [38].
The regular hCG and hyperglycosylated hCG degradation
pathways involve elastase and other proteases secreted by
Table 1: Occurrence of regular hCG, hyperglycosylated hCG and hyperglycosylated hCG free β in serum and urine samples [30-34,41-
43,45-59].
Regular hCG Hyperglycosylated hCG Hyperglycosylated hCG free β
1. Pregnancy
Early pregnancy (3–5 weeks) ± ✓✓✓ ✓
General Pregnancy (6 weeks – term) ✓✓✓ ✓ ✓
Biochemical pregnancy ✓✓✓ ± MK ±
Spontaneous abortion ✓✓✓ ± MK ±
Ectopic pregnancy ✓✓✓ ± MK ±
Down syndrome pregnancy ✓✓✓ MK ✓ MK ✓ MK
Preeclampsia ✓✓✓ ± MK ±
Pituitary ✓✓✓ X ✓
2. Neoplasia
Hydatidiform mole ✓✓✓ ✓ ±
Invasive mole ✓✓ ✓
Choriocarcinoma ± ✓✓✓ MK ✓
Quiescent trophoblastic disease ✓✓✓ X MK X
Placental site trophoblastic tumor ✓ ± ✓✓✓ MK
Testicular germ cell tumor ± ✓✓✓ MK ✓
Non-gestational malignancies ± ± ✓✓✓ MK
All variants are present in both serum and urine samples. In this table, ✓✓✓ indicates principal hCG-form detected, ✓ indicates a key hCG-form 
always present, ± indicates absent or detected at very low levels, X indicates complete absence. ✓✓✓ MK and ✓ MK indicate elevated 
concentration is a marker for disorder, ± MK and X MK indicate deficiency or absence is a marker for disorder.Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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macrophages associated with tumor tissue or present in
the circulation [39]. These cleave or nick hCG at β-subunit
44–45 or 47–48 [18,39], generating a nicked regular hCG
and a nicked hyperglycosylated hCG, a nicked hCG free β
and nicked hyperglycosylated hCG free β (Figure 3). These
same enzymes progress further to cleave and release the C-
terminal peptide on the nicked molecules (βCTP, β resi-
dues 93–145) generating nicked hCG missing βCTP,
nicked hyperglycosylated hCG missing βCTP, nicked hCG
free β missing βCTP and nicked hyperglycosylated free β
missing βCTP [18,25,39]. This is 15 variants, all found in
serum and urine samples in normal or abnormal pregnan-
cies, gestational trophoblastic diseases or non-gestational
malignancies (Figure 3).
Of these 15 variants, just 5 are natural synthetic products
made by the placenta in pregnancy or by non-trophoblas-
tic malignancies, regular hCG, hyperglycosylated hCG,
hyperglycosylated hCG free β and free α-subunit and O-
glycosylated free α-subunit. The other 10 variants are deg-
radational product, from macrophage cleavage and cleav-
age by proteases in the circulation and the kidney.
Trophoblast cells are the active cells of the placenta (Fig-
ure 4). Fused trophoblast cells or syncytiotrophoblast pro-
duce the hormone regular hCG [40]. These same cells
make an excess of α-subunit which is secreted as free α-
subunit [37,40]. Initial studies indicated that cytotro-
phoblast cells hyperglycosylated hCG [40,41]. Hyperglyc-
osylated hCG is an autocrine factor, it functions separate
to regular hCG to promote invasion at implantation of
pregnancy and malignancy in gestational trophoblastic
diseases [41-44]. Recent studied by Handschuh and col-
leagues show that hyperglycosylated hCG is made only by
the extravillous invasive cytotrophoblast cells [44], the
cell that terminate anchoring villi and invade the myo-
metrium. These same cells make an excess of α-subunit
which is secreted as free α-subunit and O-glycosylated free
α-subunit [37,40]. It is noteworthy that free α-subunit has
no known biological function, it is a biological waste
product [37].
Non-gestational malignancies produce hyperglycosylated
free β [14,31-34], as demonstrated this acts as an auto-
crine factor directly promoting cancer cell growth and
malignancy. Clearly, 3 of the 5 synthesized variants of
hCG are independent molecules, hormones or autocrines,
with separate functions, regular hCG, hyperglycosylated
hCG and hyperglycosylated hCG free β.
Hyperglycosylated hCG is the extravillous invasion
cytotrophoblast cell invasion signal [40-44], and is pro-
duced in states characterized by cytotrophoblast cells or
invasion (Table 1). It is the principal or sole form of hCG
produced in the first week of pregnancy, following
implantation of the fetus (Table 2) [43,45-47]. Unduly
low levels of hyperglycosylated hCG clearly mark failing
pregnancies, whether a biochemical pregnancy or early
pregnancy loss, spontaneous abortion or ectopic preg-
nancy [43,45-47]. While minimally present in hydatidi-
form mole cases, rising proportions of hyperglycosylated
hCG mark invasive hydatidiform mole (invasive mole)
and development and advancement of choriocarcinoma
(Table 1) [41-44,48-50]. Hyperglycosylated hCG can also
differentiate invasive and non-invasive (quiescent tro-
phoblastic disease) gestational trophoblastic diseases
[43,49]. Hyperglycosylated hCG similarly marks retrodif-
ferentiation to cytotrophoblast cells and cancer advance-
ment in testicular germ cell malignancy cases [42,48].
Hyperglycosylated hCG has also been used as an
improved marker for fetuses with Down syndrome, in
both the first and second trimesters of pregnancy [51,52].
It is also an outstanding marker for predicting third tri-
mester hypertensive disorders and preeclampsia in the
second trimester of pregnancy [53].
Table 2: Detection of total hCG, hyperglycosylated hCG and hyperglycosylated hCG free β in pregnancy serum [43,45-48].
Gestation age (weeks since last menses) N Total hCG
Median (mIU/ml)
Hyperglycosylated hCG
(%) mean ± SD
Hyperglycosylated hCG free β (%) mean ± SD
3 weeks (implantation) n = 5 22 89 ± 24% 12 ± 22%
4 weeks (missing menses) n = 16 239 49 ± 21% 7.3 ± 5.9%
5 weeks n = 27 3,683 36 ± 13% 1.7 ± 0.75%
6 weeks n = 25 16,850 21 ± 14% 1.4 ± 0.63%
7 weeks n = 22 32,095 16 ± 13% 1.0 ± 0.24%
8 weeks n = 33 95,282 7.0 ± 5.4% 0.99 ± 0.51%
9 weeks n = 7 128,300 5.1 ± 4.4% 0.92 ± 0.35%
10 weeks n = 8 102,750 4.3 ± 3.1% 0.68 ± 0.47%
11 – 13 weeks n = 21 95,650 2.3 ± 1.5% 0.67 ± 0.33%
14 – 17 weeks n = 57 32,275 1.3 ± 0.61% 0.62 ± 0.26%
18 – 26 weeks n = 62 21,250 0.65 ± 0.60% 0.55 ± 0.42%
27 – 40 weeks n = 49 21,025 0.36 ± 0.16% 0.47 ± 0.19%
Proportion hyperglycosylated hCG and hyperglycosylated hCG free β is the concentrations measured as a proportion of total hCG. SD is standard 
deviation. Gestational age is 3 day plus and 3 days minus specified week. So that data for 6 weeks pregnancy is 5 weeks 4 days to 6 weeks 3 days.Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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Outline of the structures of the 15 common hCG variants present in serum and urine samples in either pregnancy, gestational  trophoblastic disease or other malignancy Figure 3
Outline of the structures of the 15 common hCG variants present in serum and urine samples in either preg-
nancy, gestational trophoblastic disease or other malignancy. Numbers refer to subunit polypeptide amino acid num-
bers (as in 1 and 145 in the 145 amino acid long β-subunit), O refers to O-linked and N to N-linked oligosaccharides. OO and 
NN refer to large or hyperglycosylated oligosaccharides. α is α-subunit and β is β-subunit. βCTP is the C-terminal segment 
(residues 93–145) on the regular or hyperglycosylated hCG β-subunit.Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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It is important to fully understand the differentiation of
trophoblast cells which separate production of hyperglyc-
osylated hCG and regular hCG (Figure 4). Stem cytotro-
phoblast cells differentiate to make extravillous invasive
cytotrophoblasts [54], which produce hyperglycosylated
hCG (Figure 4). They also differentiate to make villous
cytotrophoblast cells which do not produce hyperglyco-
sylated hCG(Figure 4). These fuse to form multinucleated
syncytiotrophoblast cells, with 2 to 50 nulei [54]. The
fusion of cytotrophoblast cells is controlled and pro-
moted by regular hCG [55]. Cytotrophoblast cells are the
principal cells present at the time of pregnancy implanta-
tion. These cells rapidly differentiate to extravillous inva-
sive cytotrophoblast, and villous cytotrophoblast, which
fuse to syncytiotrophoblast as pregnancy advances (Figure
4) [54,55]. In choriocarcinoma and testicular germ cell
malignancies cytotrophoblast cell predominate. It
appears that the carcinogenesis process le makes a non-
differentiating non-villous invasive cytotrophoblast cells
producing hyperglycosylated hCG [42]. Thus hyperglyco-
sylated hCG is a potent marker for these malignancies. In
Down syndrome pregnancies, trisomy 21 limits the differ-
entiation of villopus cytotrophoblast cells leading to an
accumulation of these cells and hyperglycosylated hCG
[56]. This is apparently due to a failure of regular hCG-
promoted differentiation [56]. It is for this reason that
hyperglycosylated hCG is a marker of Down syndrome in
the first and second trimester of pregnancy.
Hyperglycosylated hCG free β is produced at the time of
implantation in very early pregnancy, and at very low pro-
portions throughout the length of pregnancy (Table 2).
While present at low levels, it is widely used in predicting
Down syndrome in the first and second trimesters of preg-
nancy [57]. The hyperglycosylated hCG free β is produced
in other or non-trophoblastic malignancies. A portion of
almost every human malignancy advanced, retrodifferen-
tiates and produces hyperglycosylated hCG free β [30-
38,58-62]. Hyperglycosylated hCG free β production also
distinguishes placental site trophoblastic tumors from
other forms of gestational trophoblastic disease (Table 1).
All told, regular hCG, hyperglycosylated hCG and hyperg-
lycosylated hCG free β are widespread in pregnancy, preg-
nancy abnormalities, trophoblastic malignancies and
other or non-trophoblastic malignancies, with each form
predominating in different disorders (Table 1). These 3
molecules plus ten degradation products constitute the 13
forms of hCG β-subunit present in serum or urine samples
under different conditions (Figure 3). Ideally a total hCG
tests should detect all of these hCG-related molecules to
optimal monitor pregnancy, gestational trophoblastic dis-
eases and cancer cases.
Structure
The peptide structure of the hCG group of molecules was
established by Bahl and colleagues in 1972 [63] and con-
firmed and refined by Morgan and colleagues in 1975
(Figure 1) [64]. Oligosaccharides constitute approxi-
mately 25–30% of the molecular weight of regular hCG.
The N- and O-linked oligosaccharide structures of regular
hCG were first determined by Kessler and colleagues
[65,66], and refined and confirmed by Mizouchi and
Kobata in 1980 [67], further refined by Elliott and col-
leagues in 1997 [18] and by Kobata and Takeuchi in 1999
[19]. As illustrated in Figure 1, regular hCG, molecular
weight 36,000, comprises a 145 amino acid β-subunit and
a 92 amino acid α-subunit. There are 2 N-linked oligosac-
charides on the α-subunit of hCG and 2 N-linked oli-
gosaccharides on the β-subunit of hCG. There are also 4
O-linked oligosaccharides on the C-terminal peptide
region of the β-subunit of hCG (Figure 1).
Trisaccharide O-linked oligosaccharides are present on
the C-terminal peptide segment of regular hCG (Figure 2)
[18,19]. A Full Bi (biantennary) and a Partial Bi structure
are present at the 2 N-linked oligosaccharide sites on the
α-subunit of regular hCG and a Full Bi and Full Bi w/fuc
biantennary structure are present at the 2 N-linked oli-
gosaccharide sites on the β-subunit of regular hCG
[18,19].
Between 1985 and 1997 Cole and colleagues examined
the structure of the hCG produced in invasive trophoblas-
tic disease, choriocarcinoma, and showed it to be different
to that on regular hCG [18,68,69]. As found, this invasive
cell hCG, whether from early pregnancy or choriocarci-
The differentiation of trophoblast cells in placental villi [54] Figure 4
The differentiation of trophoblast cells in placental 
villi [54]. Fusion of villous cytotrophoblast cells is controlled 
by regular hCG [55]. Extravillous invasive cytotrophoblast 
cells produce hyperglycosylated hCG [44], while fused syncy-
tiotrophoblast cells make regular hCG [40-42].Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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noma had double size hexasaccharide O-linked oligosac-
charides and larger (triantennary) N-linked
oligosaccharides (Figure 2). This molecule was named
hyperglycosylated hCG. No difference was observed in
hCG peptide sequence, only in the oligosaccharide side
chains [18]. Hexasaccharides replaced trisaccharides on
O-linked oligosaccharides of hyperglycosylated hCG. Full
Tri (triantennary), Full Tri w/fuc and Partial Tri structures
replaced the Full Bi, Full Bi w/fuc and Partial Bi bianten-
nary oligosaccharides at the N-linkage sites on hyperglyc-
osylated hCG. These increased the molecular weight of
hyperglycosylated hCG from approximately 36,000 (regu-
lar hCG) to approximate 40,500. The molecular weights
are approximate (± 1000) due to variability in sialic acid
content [18,19]. These oligosaccharide structures on regu-
lar and hyperglycosylated hCG have all now been con-
firmed by two other groups using alternate
oligosaccharide structure methods [19,36,42,70].
Variations are found in the N-linked and O-linked oli-
gosaccharide structures on hCG with differences in cellu-
lar metabolism and different expression of
glycosyltransferase activities (18,19,36). In 1997 it was
demonstrated that the 4 O-linked oligosaccharides are the
principal difference between choriocarcinoma or testicu-
lar germ cell malignancy hyperglycosylated hCG and preg-
nancy regular hCG [18,42]. There are 2 principal types of
O-linked oligosaccharides (Figure 2), trisaccharide and
hexasaccharide. While first trimester normal pregnancy
urine hCG contained 12.3 to 19% of the hexasaccharide
sugar structure (regular hCG, n = 6 individuals, mean =
15.6%), choriocarcinoma urine hCG contains 60 to 100%
hexasaccharide structures (hyperglycosylated hCG, n = 6
individuals, mean = 74.2%), 5-fold more than first trimes-
ter pregnancy [18]. A smaller difference was observed with
the 4 N-linked oligosaccharide structures on pregnancy
and choriocarcinoma molecules [18]. While 6 first trimes-
ter pregnancy samples contained an average of 10.3% tri-
antennary structures at the four N-linked sites on hCG, 5
choriocarcinoma cases contained 33% of the triantennary
structures (3-fold more than first trimester pregnancy)
[18,19,42]. The largest difference between regular hCG
and hyperglycosylated hCG is at the O-linked oligosac-
charides.
In 2006 the oligosaccharides were evaluated for the first
time on a site by site basis using mass spectrometry meth-
ods with multiple regular hCG and hyperglycosylated
hCG preparations from pregnancy, choriocarcinoma and
testicular germ cell malignancies [36]. Researchers found
a greater fucose content on N-linked oligosaccharides in
cancer cases [36]. They demonstrated site-specific differ-
ence in O-linked oligosaccharides. They showed the con-
stant presence of predominantly hexasaccharide
structures in pregnancy and choriocarcinoma at Serine
residue 121 [68–89%], with variable structures on Ser
127, 132 and 138, primarily trisaccharide structures on
regular hCG in pregnancy and hexasaccharide structures
on hyperglycosylated hCG in choriocarcinoma [36]. In
conclusion, combining results, it appears that differences
in hCG β-subunit O-glycosylation at 3 sites, Ser 127, 132
and 138, are the principal discriminator of regular hCG
and hyperglycosylated hCG [18,19,36].
Here we refer to pregnancy hCG as regular hCG and cho-
riocarcinoma hCG as hyperglycosylated hCG. With the
advent of hyperglycosylated hCG antibodies and very spe-
cific immunoassays [71,72], this larger form of hCG was
identified in urine samples considered too dilute in hCG
for analysis of oligosaccharide structures. By these meth-
ods, hyperglycosylated molecules were shown to be 96%
of total hCG in urine samples and 89% in serum samples
(Table 2) at the time of embryo implantation
[43,45,46,73]. The proportions of hyperglycosylated hCG
molecules rapidly decline in the weeks following implan-
tation, averaging 68% and 49% in urine and serum sam-
ples at the time of missing menses, 50% and 36% at 5
weeks of gestation, 25% and 21% at 6 weeks of gestation,
and < 1.5% in the second and third trimesters of preg-
nancy (Table 2) [45,46,74].
The free β-subunit of hCG detected in choriocarcinoma
patient urine and in urine from individuals with non-tro-
phoblastic neoplasm is larger than the β-subunit isolated
from regular hCG dimer. Larger oligosaccharide side
chains have been indicated [75-77]. Examination of the
structure of the free β-subunit of hCG reveals molecules
with a high proportion of fucosylated trianntenary N-
linked oligosaccharide structures and hexasaccharide O-
linked oligosaccharides, analogous to hyperglycosylated
hCG [36]. This explains the larger molecular size for hCG
free  β observed in cancer cases. The name hyperglyco-
sylated hCG free β is adopted for this molecule. It appears
that the free α-subunit of hCG receives larger oligosaccha-
ride side chains than the α-subunit of hCG dimer [37],
and that the free β-subunit like the free α also is hypergly-
cosylated.
Dissociation, cleavage and clearance
In the previous section we discussed the structures of the
regular hCG, hyperglycosylated hCG, hyperglycosylated
hCG free β and free α-subunit made by trophoblast and
cancer cells. Here we discuss the dissociation, cleavage
and clearance of these hCG forms, or the synthesis and
structure of the hCG degradation intermediates. Figure 5
summarizes the dissociation, cleavage and circulatory
clearance pathways of hCG, hyperglycosylated hCG and
hyperglycosylated hCG free β [39,78-88].Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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As an initial step, the dimers regular hCG and hyperglyco-
sylated hCG are either slowly cleaved (nicked) or slowly
dissociated into α and β subunits (Figure 5). The dissoci-
ation half-time of dimers into subunits is 700 ± 78 hours
at 37°C [78]. Hyperglycosylated hCG dissociates much
more rapidly that regular hCG (140 ± hours at 37°C [39]).
A macrophage or circulating leukocyte elastase protease
cleaves hCG β-subunit at Val residue 44 (residue 44–45
cleavage) or Gly residue 47 (residue 47–48 cleavage) gen-
erating nicked hCG (Figure 1) [39,78]. Nicked hCG is 30-
fold less stable than regular hCG (dissociation half time
22 ± 5.2 hr. at 37°C [78]) rapidly dissociating releasing a
free α-subunit and a nicked hCG free β. Similarly, dissoci-
ated hCG β-subunit is rapidly cleaved by leukocyte
elastase to make nicked hCG free β. Both nicking and dis-
sociation eliminate hCG hormone activity (shown by
ability to bind corpus luteum hCG/LH receptor and to
promote progesterone production [39]). Dimer is cleared
from the circulation very slowly (clearance half-life 35.6 ±
8.0 hr. [82,84]), hCG free β is cleared 10-fold faster (3.93
± 0.68 hr. [83,84]). As such the combination of nicking
and dissociation, in either order, leads to the rapid deacti-
vation and clearance of regular or hyperglycosylated hCG
[78].
Nicked hCG or nicked hCG free β, while cleaved at 44–45
or 47–48, remain structurally intact due to 5 disulfide
The dissociation, degradation and clearance pathways of regular hCG [39,78-87] Figure 5
The dissociation, degradation and clearance pathways of regular hCG [39,78-87]. Metabolic clearance half-times 
(MCR) are those published by Wehman and colleagues [85-88]. Similar degradation and clearance pathways are predicted for 
hyperglycosylated hCG and hyperglycosylated hCG free β with an end product of urine β-subunit core fragment.Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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linkages between the component peptides. Further degra-
dation of hCG by leukocyte elastase leads to cleavage of β-
subunit at Leu residue 92 [39]. The peptide 93–145 the
βCTP is not held by disulfide linkages and leads to nicked
dimer missing the βCTP or nicked hCG free β missing
βCTP [18,32,39]. Nicked dimer missing the βCTP is rap-
idly degraded to nicked hCG free β missing the βCTP (Fig-
ure 5). The nicked hCG free β missing the βCTP made by
either pathway is rapidly degraded in the kidney by exo-
proteinases and glycosidases to β-subunit core fragment,
the terminal degradation product of regular hCG, hCG
free β, hyperglycosylated hCG and hyperglycosylated hCG
free β [85-88]. β-subunit core fragment is β-subunit resi-
dues 6–40 linked to residues 55–92, held together by 5
disulfide linkages. It has degraded N-linked oligosaccha-
rides, missing the non-reducing terminal sialic acid, galac-
tose and N-acetylglucosamine residues and fucose
residues so terminates in mannose [85]. As shown, injec-
tion of pure CHO cell recombinant regular hCG (contains
no nicked, hyperglycosylated or dissociated hCG compo-
nents) into the human circulation leads to excretion of β-
subunit core fragment in the urine [88], clearly confirm-
ing the degradation pathway.
Nicking and cleavage to make β-subunit core fragment
continues throughout pregnancy deactivating hCG [4]. In
first trimester pregnancy serum, 9% of hCG dimer mole-
cules are nicked, all free β molecules are also nicked, in the
last 2 months of gestation 21% of dimer molecules are
nicked and all free β molecules are nicked [39,78]. In
pregnancy urine samples, β-subunit core fragment con-
centration or the degradation end product concentration
is relatively small in the first weeks of gestation, it equals
hCG dimer concentration at 6–7 weeks of pregnancy. β-
core fragment concentrations then exceeds dimer concen-
trations in urine thereafter, 7 weeks to term [14,89,90].
Mean  β-core fragment concentrations average 58% of
urine hCG concentrations (mean proportion) at 5 weeks
gestation, 105% at 7 weeks gestation rising to 305% of
hCG concentrations in the final month of pregnancy
[14,89,90]. β-subunit core fragment is the principal hCG
related molecule in pregnancy urine samples. In chorio-
carcinoma cases, 100% hyperglycosylated hCG may be
present in serum samples, yet either the hyperglycosylated
hCG or β-subunit core fragment may predominate in par-
allel urine samples [91,92].
All non-trophoblastic malignancies produce primarily
hyperglycosylated hCG free β [31,30-34]. In most cases, as
a result of macrophage elastase activity at tumor site, the
degradation product β-subunit core fragment is detected
in corresponding urine samples [14,93-95]. Considering
the extremely low levels of hyperglycosylated hCG free β
produced by non-trophoblastic malignancies and their
rapid clearance from the circulation, urine β-subunit core
fragment may be a more sensitive or more measurable
tumor marker than serum hyperglycosylated hCG free β
[14,93-95].
It is common to find residual nicked hCG or nicked hCG
missing  βCTP in serum or β-subunit core fragment in
urine, the products of degradation, in the weeks following
parturition of pregnancy or surgical evacuation of hyda-
tidiform mole or tumor. It is important in these cases to
detect nicked hCG and nicked hCG missing βCTP in mon-
itoring serum and β-core fragment in monitoring urine
following evacuation of ectopic pregnancy, parturition,
evacuation of hydatidiform mole and choriocarcinoma
and non-trophoblastic malignancy malignancy to be sure
that all tissue is removed.
In the preceding section we examine the structures of reg-
ular hCG, hyperglycosylated hCG and hyperglycosylated
hCG free β as produced by cells. In this section we show
how elastase and other proteases and glycosidase convert
3 forms of hCG β-subunit in serum and urine into 13
forms (Figure 3). Different secreted and degraded forms of
hCG may best mark different conditions (Table 1). We
emphasize again, it is important when considering a total
hCG assay and the structure and degradation findings pre-
sented here, to select an assay detecting all form of hCG β-
subunit. Regular hCG may mark a normal pregnancy,
hyperglycosylated hCG may best mark gestational tro-
phoblastic diseases, hyperglycosylated hCG free β may
best mark a Down syndrome pregnancy, nicked hCG
missing βCTP may best mark clearing hCG at parturition
or following termination, and urine β-subunit core frag-
ment ay best mark non-trophoblastic malignancies.
Biological functions
Regular hCG
Placental hCG replaces pituitary LH in controlling proges-
terone production at the initiation of pregnancy, from
implantation of pregnancy (~3 weeks gestation) to 6
weeks of gestation. The syncytiotrophoblast cells make
progesterone independent of hCG stimulation from 6
weeks gestation until term. Serum concentrations of hCG,
however, rise logarithmically and continuously from
implantation of pregnancy to a peak at 10 weeks of gesta-
tion (Table 2), levels then fell to about one fifth peak lev-
els and remained at this level to term [14]. hCG
concentration seems to have no relationship to their need
for promoting progesterone production. That the function
of hCG was solely promoting progesterone production,
however, was a dogma for almost 80 years (1), even
though it was only biologically active for 3 weeks of its 37
week production. This made no biological sense.
Research by multiple groups in the past 10 years shows a
much more logical primary function on hCG, maintain-Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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ing maternal blood supply to support hemochorial pla-
centation and nutritional support of fetus (Figure 6, Panel
A – C) [96-101]. hCG maintains angiogenesis in the myo-
metrial spiral arteries through the length of pregnancy act-
ing on LH/hCG receptors on the spiral arteries [96-101].
It has also been shown that hCG promotes the fusion of
villous cytotrophoblast cells to syncytiotrophoblast (Fig-
ures 4, Figure 6, Panel A-C) [102]. Both of these biological
functions are critical to efficient placentation in humans.
This is the more logical prime function of regular hCG
through the length of gestation.
Hyperglycosylated hCG
As discussed, hyperglycosylated hCG is the variant of hCG
produced by extravillous invasive cytotrophoblast cells.
Examining choriocarcinoma cell lines and testicular germ
cell cytotrophoblast cell lines, Cole et al. [41,42] showed
that addition of pure hyperglycosylated hCG and not pure
regular hCG to first trimester cytotrophoblast cells (vil-
lous plus extra-villous cells), and to choriocarcinoma
cytotrophoblast cells, promotes growth and invasion
across membranes in vitro. It also promotes extensive
invasion, growth and malignancy by choriocarcinoma cell
transplanted into nude mice in vivo [41,42] Hyperglyco-
sylated hCG is an autocrine factor produced by extravil-
lous invasive cytotrophoblast cells and acting on these
same cells to promote growth of the cells and invasion of
other cell by the cells [41,42]. Other studies by Hamade et
al. [103] and Lei et al. [104], show that the form of hCG
produced by non-villous cytotrophoblast cells (hypergly-
cosylated hCG) is responsible for promotion of invasion,
growth and malignancy in choriocarcinoma cells in vivo
and in vitro, confirming these findings. Multiple articles
have confirmed that extravillous invasive cytotrophoblast
cells are the invasive cells of the placenta [105-108].
Handschuh et al. [44] confirm that hyperglycosylated
hCG is the invasion signal for these cells. Hyperglyco-
sylated hCG has been shown to drive invasion in early
pregnancy by extravillous invasive cytotrophoblast cells
(Figure 6, Panel A) [42], and to be a critical signal for suc-
cessful pregnancy implantation (Figure 6, panel A) [43].
As published, deficient hyperglycosylated hCG leads to
biochemical pregnancies and pregnancy failures [43,45-
47]. All told, hyperglycosylated hCG is produced by
extravillous invasive cytotrophoblast cells and acts on
these same cells to promote cell growth and invasion, as
in implantation of pregnancy and malignancy in cytotro-
phoblast cell cancers (Figure 6, Panel A).
While it has been shown that hyperglycosylated hCG pro-
motes cell growth through blocking apoptosis [103], only
questionable data identifies a receptor for its action. Khoo
et al. [109], showed that the TGFβ RII receptor binds a
molecule of the size of hyperglycosylated hCG to promote
invasion. Structural homology has been noted between
the peptide structure of hCG and TGFβ. hCG subunits
contain TGFβ cysteine knot structures within the three
dimensional core of the molecule [110]. Unraveling of the
core as may occur in response to the peptide folding
around the larger sugar structures on hyperglycosylated
hCG could expose the cysteine knot structures and lead to
TGFβ receptor interaction. TGFβ has shown to be critical
to extravillous cytotrophoblast cell invasion, implanta-
tion and apoptosis, so that the concept of hyperglyco-
sylated hCG as an apoptosis blocker working by
antagonizing this receptor seems feasible [111-113].
Research demonstrating the nature of the hyperglyco-
sylated hCG receptor is urgently needed to complete this
story.
Regular hCG – hyperglycosylated hCG partnership
A trophoblast villus is a structural projection of trophob-
last tissue, and is the functional unit of trophoblast tissue
(Figure 6, Panel B). There are a combinations of anchor-
ing villi and floating villi. Anchoring villi literally anchor
villi in the myometrium, they are also the invasive ele-
ment (Figure 6, Panel B), with extravillous cytotrophob-
last cells producing hyperglycosylated hCG driving
invasion deeper and deeper into the myometrium
[42,43,114,115]. It is floating villi that are active in nutri-
tion transport meeting with the blood from the maternal
spiral arteries (Figure 6, panel C) [114,115]. In pregnancy,
hundreds of trophoblast villi invade through the deciduas
into the uterine myometrium. Figure 6, panel B illustrates
6–8 week gestation villous tissue. It comprises mostly syn-
cytiotrophoblast tissue; beneath these are villous cytotro-
phoblast cells awaiting fusing into syncytiotrophoblast
cells. Regular hCG is made by the syncytiotrophoblast
tcells then acts to promote the continuous fusion of vil-
lous cytotrophoblast cells to villous syncytiotrophoblast
cells (Figure 6, panel B) [55]. Regular hCG circulates in the
blood and promotes the growth and expansion of the
myometrial spiral arteries to reach the villous tissue and to
bleed over the villous tissue. Regular hCG circulates in the
blood and promotes the growth and expansion of the
myometrial spiral arteries, the source of blood to the vil-
lous area after 10 weeks of gestation (Figures 6, Panel B
and C).
Throughout the first trimester the villi invade deep into
the myometrium, under the influence of hyperglyco-
sylated hCG produced by extravillous invasive cytotro-
phoblast, reaching one third the thickness of the
myometrium. Regular hCG produced by villous syncytio-
trophoblast promotes the growth and expansion of the
myometrial spiral arteries (Figure 6, Panel B) [115-118].
The villous area starts to be bathed by blood, directly orig-
inated from the spiral arteries at around 10 weeks of ges-
tation, the time of the regular hCG and hyperglycosylated
hCG peak, competent hemochorial placentation thenReproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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commences to provide ultra-efficient nutrition to the fetus
(Figure 6, panel C) [114-118]. Floating villi are sur-
rounded by syncytiotrophoblast cells form a syncytiotro-
phoblast membrane. The spiral arteries bleed directly
onto the membrane, flooding with blood, nutrients are
then very efficiently taken up into the villi and the fetal cir-
culation (Figure 6, Panel C). This is hemochorial placen-
tation [114-118]. Regular hCG continues to be made by
syncytiotrophoblast cells on the deeply invaded villous
tissue, it promotes continued fusion of trophoblast cells
and the continued growth of spiral arteries.
Hemochorial placentation (Figure 6, Panel C) is in many
just the end result of a combination of hyperglycosylated
hCG driven invasion deep into the myometrium and reg-
ular hCG hormonal activity driving the growth and devel-
opment of the spiral arteries such that they bleed onto the
invaded villi. Hemochorial placentation could be consid-
ered as simply the consequences of regular hCG and
hyperglycosylated hCG action or the product of the regu-
lar hCG/hyperglycosylated hCG partnership. As presented
in the following section of this review, about evolution, it
is the evolution of hCG that seemingly caused hemocho-
rial placentation or efficient placentation to evolve and its
advancement in circulating concentration drove it
towards the human system, the most efficient of any spe-
cies [119]. This product of hCG/hyperglycosylated hCG
partnership may not be perfect, as present in a later sec-
tion of this review the high incidence of pregnancy fail-
ures in humans is due to deficiencies in regular hCG/
hyperglycosylated hCG action [43,45-47,119]. Preec-
lampsia, a unique human gestational hypertensive disor-
der is seemingly due to failure of hemochorial
placentation and may be caused by deficient hyperglyco-
sylated hCG invasion or regular hCG angiogenesis [119].
Preeclampsia, a unique human gestational hypertensive
disorder is seemingly of failure of hemochorial placenta-
tion and may be caused by deficient hyperglycosylated
hCG invasion or regular hCG angiogenesis [119]. All told
this partnership of regular hCG and hyperglycosylated
hCG, two oddball variants with the same polypeptide
sequences, is critical to human placentation and to the
human reproductive process.
Hyperglycosylated hCG free β
Studies by Acevedo and colleagues show the presence of
hCG free β in the membranes of all cancer cell lines and
in all histological samples of malignancies [58,120].
Whilst this data is considered rather controversial, new
data appears to confirm it in cervical cancer cells although
the justifications are somewhat different [121]. Other
studies indicate an association between detection of
hyperglycosylated hCG free β in serum samples or β-sub-
unit core fragment, its degradation product, in a urine
samples in cases with poor grade and advanced stage can-
cer, or poor outcome malignancy [32,34,122,123]. In a
literature review of independent articles investigating free
β as a prognostic marker in carcinoma, 12 of the 13 stud-
ies demonstrated a clear correlation between expression
of hyperglycosylated hCG/hCG free β and poor prognosis
[32,59]. These studies collectively indicate that expression
of free β invokes a negative outcome in human malignan-
cies either directly, or indirectly, and thus an association
between free β expression and malignancy has been pro-
posed. Multiple reports now indicate that free β may have
a specific role in malignant transformation of cells
[58,61,62,121]. In these, and other studies, direct stimu-
lation of non-gestational malignant cell growth has been
demonstrated by the action of free β and where endog-
enous free β is produced, growth can be inhibited by anti
free β antibodies [30,32,38,59,124].
Clearly, free β has a significant role to play in non-gesta-
tional neoplasm biochemistry, either as a promoter caus-
ing poor malignancy outcome or as an element involved
in malignant transformation. Indeed, efforts have been
directed toward using different free β derivatives as vac-
cines in the treatment of non-gestational malignancies.
Success has been reported, with free β immunity improv-
ing cancer outcome or cancer survival [125-129]. The
association of free β detection and poor prognosis, in
combination with site specific free β vaccine technology
suggests a plausible route to the development of adjuvant
Villous placental tissue, cytotrophoblast and syncytiotrophoblast cells, and regular hCG and hyperglycosylated hCG function Figure 6 (see previous page)
Villous placental tissue, cytotrophoblast and syncytiotrophoblast cells, and regular hCG and hyperglycosylated 
hCG function. Panel A illustrated blastocyst implantation and engulfment and trophoblast invasion at 3–5 weeks of gestation. 
Arrows illustrates the biological functions of regular hCG and hyperglycosylated hCG. Mononuclear cells are cytotrophoblast 
cells, cells with multiple nuclei (black circles) represen syncytiotrophoblast cells. In Panel B villous trophoblast formation and 
function are illustrated at 6–8 weeks of gestation [44,54,114,115]. Figure illustrates villous trophoblast (anchoring villus and 
floating villus) growth 5 to 10 weeks of gestation, and invasion of the decidua and myometrium in establishing hemochorial pla-
centation. Panel C illustrates functional hemochorial placentation in floating villus at 10–12 weeks of gestation after invasion is 
complete [114-118]. Cells with varying numbers of multiple nuclei (black circles) represent villous syncytiotrophoblast (VSyn), 
mononuclear cells are villous cytotrophoblast (VCyto) and extravillous invasive cytotrophoblast (EVICyto). Arrows shows bio-
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cancer therapies specifically targeting patients with free β
producing non-gestational tumors.
Both hyperglycosylated hCG and free β promote cancer
cell growth, invasion and malignancy [30,32,38,41,42,44,
59,124], similarly, both hyperglycosylated hCG and free β
function by blocking or antagonizing apoptosis causing
cell growth [30,32,59,60,103,121]. In the action of both
hyperglycosylated hCG and free β the use of the TGFβ
receptor is indicated [30,32,109-114]. As reported, free β
is produced by bladder cancer cells and inhibits TGFβ
activity in bladder cancer cells [33] and free β-subunit
opposes TGFβ growth suppressing functions in bladder
cancer cells [32]. It is inferred that both hyperglycosylated
hCG and hyperglycosylated hCG free β function similarly,
both promoting cell growth, invasion and malignancy by
blocking apoptosis through antagonizing a TGFβ recep-
tor.
Evolution
Chorionic gonadotropin (CG) is part of a family of hor-
mones that includes LH, follicle stimulating hormone and
thyroid stimulating hormone. These are the glycoprotein
hormones that share a common α-subunit coded by a sin-
gle gene, and a separate β-subunit which dictates hor-
mone function [130,131]. In 1980 Fiddes and Goodman
[130], examined the DNA sequence for the β-subunits of
CG and LH and showed that the evolution of CG from LH
was by a single deletion mutation in LH β-subunit DNA
and read-through into the 3'-untranslated region occur-
ring in early simian primates. In 2002 Maston and Ruvolo
[131], examined the DNA sequences of the β-subunit of
CG in 14 primates and showed that the genes to make CG
and its variants were not present in prosimians or primi-
tive primates (example: Lemur), but evolved by the indi-
cated deletion mutation with early simian primates
(example: platyrrhine or new world monkey). Multiple
mutation leading to DNA and amino acid sequence
changes then occurred with the continued evolution of
the CG β-subunit genes from early simian primates to the
advanced simian primates (example: pongo or orangu-
tan) and further changes with the evolution of hominids
[131]. In summary, prosimian LH has 3 N-linked oli-
gosaccharides mean pI 8.4, from the deletion mutation
CG evolved in early simians with 5 oligosaccharides mean
pI 6.3, from a further mutation advanced simians evolved
a CG with 6 oligosaccharides mean pI 4.8, and with fur-
ther mutations hominids evolved with 8 oligosaccharides
mean pI 3.5 (Table 3).
The acidity of the evolving CG (and its variants) with
additional oligosaccharides very much affects its meta-
bolic clearance rate or circulating half times and thus
serum concentration and its effective bio-potency
[132,133]. As an example, at one extreme, regular human
CG has 8 O-linked and N-linked oligosaccharides all ter-
minating in sialic acid residues. These acidify hCG result-
ing in a molecule with a mean isoelectric point (pI) of 3.5,
and a circulating half time of 35.6 hours [82,84]. At the
other extreme, asialo hCG with no acidic sugars on oli-
gosaccharides has a pI of 8.5 and a circulating half time of
5.7 minutes [133]. Because of the acidity due to the sialic
acidic residues on each N- or O-linked oligosaccharides,
regular hCG circulates for approximately 400 times longer
than asialo hCG, raising the circulation concentration
proportionately.
The earliest CG form in early simian primates had 2 O-
linked oligosaccharides on the β-subunit at serine resi-
dues 121 and 132 and one N-linked oligosaccharide at
residue 30 [131]. This yielded a molecule with a mean pI
of 6.25 [131,135]. As a result of a point mutation at resi-
due 127 (Asn-Ser), the advanced simian primate evolved
with a CG having 3 O-linked oligosaccharides
[131,134,135], and a mean isoelectric point of 4.9 (Table
1) [135]. With the evolution of hominids, a point muta-
tion occurred at residue 138 and 15 and CG molecules
were developed with 4 O-linked and 4 N-linked oligosac-
charides [131]. The 4 O-linked 4 N-linked oligosaccharide
molecule, is the most acidic CG, pI 3.5 [82]. We deduced
from isoelectric points that the 2 and 3 O-linked oligosac-
charide 3 N-linked oligosaccharide CGs produced by early
and advanced simian primates had minimal and mid-
dling circulating half times within the wide half time
range of LH at 25 minutes and human CG at 35.6 hours.
It is concluded that with evolution from early simians to
advanced simians to humans, and the stepwise increases
in isoelectric point that circulating half-times and blood
concentrations of CG and hyperglycosylated CG increased
logarithmically.
Table 3: Parallelisms between placental implantation and invasion characteristics in primates, presence and sugar structure of CG or 
LH, and relative brain masses.
Species Implantation characteristics Depth of Invasion Sugar structures, pI Brain mass (%)
Hominids Hemochorial 1/3rd myometrium CG, 8 structures, pI 3.5 2.4%
Advanced simian primate Hemochorial 1/10th myometrium CG, 6 structures, pI 4.9 0.74%
Early simian primate Hemochorial through decidua CG, 5 structures, pI 6.3 0.17%
Prosimian primate epitheliochorial no-invasion No CG produced LH, 3 structures, pI 8.4 0.07%
Table summarizes published data [130,131,134,135,137,139,140,146].Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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Brain size in mammals is directly related to the combina-
tion of body mass and the metabolic support of the devel-
oping progeny [136]. The greater brain size, seen in
advanced primates and hominids, correlates with dispro-
portionately large energy demands by the developing
fetuses [136-142]. Numerous studies support the concept
that advanced primates, and to a greater extent humans,
have had to develop ultra efficient placentation mecha-
nisms to support the increasing nutritional demands of
the embryonic brain (Table 3) [136-146].
As shown in Table 3, the prosimian primate had an aver-
age size mammalian brain, 0.07% of body mass. In this
species, epitheliochorial placentation was sufficient. This
involves the placenta loosely attaching to the wall of the
endometrial stroma with no invasion. Nutrients and oxy-
gen had to diffuse through multiple myometrial and
endometrial stromal layers to transfer from the maternal
to fetal circulation. Hemochorial placentation started
with the early simian primate with the evolution of CG
[137,139,140,146]. In all likelihood regular CG and
hyperglycosylated CG initiated and drove hemochorial
placentation [119]. The earlier simian primate had 2 O-
linked oligosaccharides and 3 N-linked oligosaccharides,
was not very acidic, so probably cleared the circulation
quickly leaving extremely low concentrations of circulat-
ing molecules to promote invasion and angiogenesis,
leading to inefficient hemochorial placentation. The pla-
centa invaded through the thickness of the decidua only.
Placentation supported nutritional transfer necessary for a
brain of 0.17% body mass or 2.5 fold greater than prosim-
ian primates (Table 3) [137,139,140,146]. The advances
simian primate had 3 O-linked oligosaccharides, was
more acidic, so cleared the circulation at a mediocre rate
leaving mediocre concentration of circulating molecule to
promote invasion and angiogenesis. This permitted inva-
sion through the decidua to one tenth the thickness of the
myometrium [137,139,140,146]. Placentation supported
nutritional transfer necessary for a brain of 0.74% body
mass or 4.5 fold greater than the early simian brain (Table
3) [137,139,140,146].
Placentation and nutrition transfer was taken to the
extreme in the hominids. Hominid CG is very acidicwith
4 O-linked and 4 N-linked oligosaccharides with a circu-
lating half-time of 35.6 hours leading to highly elevated
levels of regular CG and hyperglycosylated CG. This led to
invasion through the decidua to one third the thickness of
the myometrium and to ultra efficient angiogenesis. Pla-
centation supported nutritional transfer necessary for a
brain of 2.4% body mass or 3 fold greater than that of
advanced simians (Table 3) [137,139,140,146].
Considering the relationship between regular CG, hyper-
glycosylated CG and hemochorial placentation, and
between advancing acidity of CG and advancing invasion
and angiogenesis, it would not be unreasonable to pro-
pose that the evolution of CG in early simians started pri-
mates on the evolution path to advanced brains, or is at
the root of the evolution of humans.
The evolution of hyperglycosylated hCG free β appears to
an end result result of the evolution regular and hypergly-
cosylated hCG. The gene for the β-subunit evolved in the
human genome. The gene for the α-subunit existed sepa-
rately as the α-subunit of glycoprotein hormones. When
cancer cells regress and retro-differentiate they express
cytotrophoblast proteins. By default hyperglycosylated
hCG free β is expressed which promotes cancer growth
and malignancy [30,32,38,58,61,62,59,124] leading to
poor prognosis [32,34,122,123].
Consequences of evolution
The human CG- and hyperglycosylated CG-driven placen-
tation model may be optimal for fetal nutrition and brain
development. In many respects placentation efficiency
has expanded to the extreme to accommodate humans
supporting a 2.4% body mass brain versus a 0.07% brain
in prosimians and many other mammals. Failure of this
extreme process, however, may be associated with life
threatening complications. Ineffective invasion into the
myometrium leads to inefficient hemochorial placenta-
tion. This leads to nutritional deficits and anoxia to the
fetus compensated for by preeclampsia in the mother
[138,142,144,145,147,148]. Preeclampsia has been
shown to be linked to unduly low hyperglycosylated hCG
levels at the time of initiation of hemochorial placenta-
tion at the end of the first trimester [149]. Preeclampsia is
one of the most life-endangering complication of preg-
nancy and occurs uniquely in humans with the fetal
demand for deep implantation and the oxygen and nutri-
tional mechanisms needed to support brain development.
With the implantation demands of the fetus, pregnancy
failures occur more commonly in humans that in any
other species. Pregnancy failures, miscarriages and bio-
chemical pregnancies or early pregnancy losses, account
for 41% of gestations in humans compared to rodents
(10%) and to a similar low percentage in all other species
[43,145,150]. Shallow implantation or ineffective inva-
sion leads to human pregnancy failures [145]. Approxi-
mately two thirds of human failures can be attributed to
inappropriate invasion [145] and are associated with
unduly low hyperglycosylated hCG concentrations
[45,73,151]. All pregnancies with normal term outcome
produce a significant proportion of hyperglycosylated
hCG at the time of implantation [43]. Similarly, two
thirds of pregnancies that fail are associated with signifi-
cant low hyperglycosylated hCG concentrations [43].
Together this data, and the established invasion promot-Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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ing function of hyperglycosylated hCG suggest that the
two thirds of failures due to placentation are the same as
the two thirds due to low hyperglycosylated hCG. It is
inferred that the high incidence of pregnancy failures, in
humans, is a consequence of deficient hyperglycosylated
hCG.
Hydatidiform mole does occur in primates [152,153].
Invasive moles, gestational trophoblastic neoplasms or
choriocarcinoma, however, have only been observed in
humans. These are malignancies of trophoblast tissue
associated with extravillous invasive cytotrophoblast cells,
driven by the production of CG-H [41,42,146-149]. It
appears that just as hyperglycosylated hCG promotes
invasion of by normal pregnancy extravillous invasive
cytotrophoblast cells during implantation, it is also
responsible for the malignancy-like invasion by cytotro-
phoblast cells in trophoblastic neoplasia. Circulating lev-
els of hyperglycosylated CG are significantly raised by
acidic glycosylation, from early simian to advanced sim-
ian primates, and then raised further by acidic glycosyla-
tion with the evolution of hominids. We deduce that only
humans have circulating hyperglycosylated CG levels at
magnitudes that can cause malignant-like states. It is
inferred that invasive gestational trophoblastic diseases
occurs uniquely in humans as a complication of the hom-
inid generation of high concentrations of the invasion
promoter hyperglycosylated CG
Considering the relationship between hyperglycosylated
hCG and trophoblast invasion, and the proposed link
between evolution of hyperglycosylated CG and primate
and human evolution, a different perspective emerges on
problems with human fecundity due to pregnancy failure,
on preeclampsia in human pregnancy and on invasive
gestational trophoblastic diseases. Do these findings and
hypotheses open new avenues for preventing pregnancy
failure and preeclampsia, and for treating or preventing
invasive gestational trophoblastic disease?
Is it conceivable that pregnancy failures can be prevented
by administration of human CG-H at the time of implan-
tation. The abundance of research showing a link between
hyperglycosylated hCG and pregnancy failure supports
such trials [43,73,151]. The lack of availability of a pure or
clinical usefully preparations of hyperglycosylated hCG at
the present time, however, limits the initiation of such tri-
als.
We question similarly the potential use of hyperglyco-
sylated hCG therapy in reducing the risk of preeclampsia
and gestation induced hypertension in high risk pregnan-
cies. It is possible that administration of hyperglyco-
sylated hCG at 10–13 weeks of gestation would ensure
appropriate completion of invasion and appropriate acti-
vation of hemochorial implantation. Risks, such as those
which may cause over-invasion or placenta percreta
would need to be taken into account. The possible preven-
tion of these disorders could have significant effect on
pregnancy complications.
The relationship between human hyperglycosylated hCG
and invasive gestational trophoblastic disease is widely
proven [41,42,146-149]. Therapy would need to involve
the blocking of hyperglycosylated hCG. This may be very
much simpler than administrating the invasion-promot-
ing agent. Three separate studies using nude mice trans-
fected with choriocarcinoma cells have shown that
blocking hyperglycosylated hCG (choriocarcinoma hCG)
production with hyperglycosylated hCG antibody or
genetic methods, halts all growth and development of
malignancy [41,103,104]. The next step is to perform
analogous studies in humans, using human antibodies to
hyperglycosylated hCG or vaccines to similarly block
malignancy. These would initially be used in patients with
chemotherapy resistant cases of choriocarcinoma, and
then later examine the prevention of invasion or malig-
nancy in patients with hydatidiform mole.
Hyperglycosylated hCG free β is produced by most
human malignancies solely as a consequence of the evo-
lution of regular and hyperglycosylated hCG for promo-
tion of hemochorial placentation. When cancer cells
regress and retro-differentiate they express cytotrophob-
last proteins. By default hyperglycosylated hCG free β is
expressed which promotes cancer growth and malignancy
[30,32,33,58,61,62,59,124] leading to poor prognosis
[32,31,122,123]. Efforts have been directed toward using
different free β derivatives as vaccines in the treatment of
non-gestational malignancies. Success has been reported,
with free β immunity improving cancer outcome or cancer
survival [125-129]. The use of site specific free β vaccine
technology suggests a plausible route to the development
of adjuvant cancer therapies specifically targeting patients
with free β producing non-gestational tumors. An hCG β-
subunit derivative vaccine is commercially available (CG
Therapeutics, Seattle, USA). It is being tested in clinical tri-
als with different non-gestational neoplasms in the USA.
Pituitary hCG
In 1976 Chen and colleagues [154], identified human
chorionic gonadotropin (hCG) in the circulation of non-
pregnant females. This was later demonstrated as being of
pituitary origin [155]. Multiple studies with post-mortem
human pituitary extracts showed that they all contained
hCG at an average concentration of 3.0% of the LH con-
centration (average 0.8 μg per gland) [156,157]. Individ-
ual pituitary glands contained varying concentrations of
hCG, 0.05 to 3.3 μg/gland [156,157]. These findings have
been confirmed multiple times, with pituitary hCG pro-Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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duction being demonstrated as part of normal reproduc-
tive physiology [43,157-164]. When considering that
hCG and LH share a common α-subunit gene [165], and
the LH β-subunit gene is buried amidst 7 hCG β-subunit
genes [165], it may be considered as no biological surprise
that the pituitary produces a small amount of hCG along
with higher concentrations of LH. Pituitary hCG has been
detected aside LH in the menstrual cycle [158-162], and
post-menopausal in response to the absence of estradiol
feedback regulation [43,162-164].
Cole and colleagues recently examined regular hCG in
371 menstrual cycles (Table 4) [166]. The menstrual
cycles averaged 28.6 ± 3.8 days (mean ± standard devia-
tion) in length, with an LH peak detected at 14.6 ± 3.1
days following the commencement of menstrual bleed-
ing. The LH peak averaged 210 ± 161 IU/L in magnitude
in urine samples (Table 4). Regular hCG was detected
(sensitivity 1 mIU/ml) around the time of the LH peak in
(LH peak +/- 4 days) in 332 of the 371 menstrual cycles
(89%) (Table 4). The average hCG concentration was 1.52
± 0.91 IU/L in positive LH peak urine samples. The major-
ity of positive regular hCG urines corresponded to the LH
peak day, with lesser numbers of urines corresponding to
1 to 4 days before and 1 to 4 after the LH peak. A correla-
tion was observed between LH concentration and the cor-
responding hCG concentration among the 332 urines,
equating hCG and LH by linear regression, r2 = 0.97; by
Bartholomew's test of ordered means, p = 0.004 [166].
It was concluded that 1.0 mIU/ml or a greater concentra-
tion of regular hCG was produced parallel to the LH peak
in 89% of menstrual cycles [166]. It was inferred that reg-
ular hCG was also produced in the 11% remaining men-
strual cycles but at levels < 1 mIU/ml. Regular hCG
promotion in the pituitary may be incidental, a byproduct
of gonadotropin releasing hormone (GnRH) promotion
of LH and follicle stimulating hormone (FSH) expression.
Regular hCG expression, however, may be purposeful. LH
has a very short circulating half life, 0.42 hrs, while hCG
has a long circulating half-time 40 hrs [81,167]. In urine
regular hCG is approximately 1% of the concentration of
LH. In the pituitary gland, however, regular hCG exists at
3% of the concentration LH [156,157]. In serum, 2-fold
higher levels of regular hCG are observed than recorded in
urine [14], while 4-fold lower levels of LH are observed
[168,169]. As such, regular hCG levels in serum may be
much more significant than observed in urine (approxi-
mately 7% of LH concentration). The serum concentra-
tion represents the concentration acting on ovarian cells.
Regular hCG may supplement the promotion of ovula-
tion by extending the LH peak range. This suggest that
slow clearing regular hCG may also have a function in
boosting the rise in progesterone levels during the begin-
ning of the luteal phase of the cycle. We infer that regular
hCG is a functional hormone during the menstrual cycle,
either in promoting ovulation or promoting progesterone
production.
The pituitary processes molecules slightly differently to
syncytiotrophoblast cells, It terminates some N-linked
sugar structures in N-acetylgalactosamine-sulfate rather
than in galactose-sialic acid (Figure 2). The 4 N-linked oli-
gosaccharides on regular hCG produced by the pituitary
terminate in N-acetylgalactosamine-sulfate, while the 4
O-linked oligosaccharides are like those made by syncyti-
otrophoblast cells terminate in galactose-sialic acid [170].
Because of the difference in N-linked oligosaccharide
structure and its acidity, pituitary regular hCG is half as
biologically potent as syncytiotrophoblast cell regular
hCG, due to a shorter circulating half-life [171].
As recorded in all medical text books, LH and FSH levels
are controlled by negative feedback to the hypothalamus
by estradiol, controlling GnRH pulses during menstrual
periods. As also recorded, estradiol feedback becomes
reduced during perimenopause years and disappears dur-
ing menopause. With this reduction, LH and FSH are nor-
mally produced at much higher levels without control at
these menopause times. What textbooks do not mention,
is that hCG produced at the time of the LH peak also
Table 4: Production of LH and regular hCG during non-gestational menstrual cycles [166].
Number of valid non-gestational menstrual cycles 371 cycles
Timing of LH peak concentration during valid menstrual cycles mean ± SD) 14.6 ± 3.1 days
Number of urines tests 11,122
Length of menstrual cycle, start of bleeding to next start of bleeding 28.6 ± 3.8 days
Of valid cycles, the mean peak LH concentration ± SD 210 ± 161 mIU/ml
Number of positive daily hCG tests, 1 IU/L sensitivity, in valid menstrual cycles 371
Proportion of menstrual cycles with positive regular hCG test, 1 IU/L sensitivity 332 (89%) cycles
Cycles with positive regular hCG test, regular hCG mean ± SD 1.52 ± 0.91 mIU/ml
Cycles with positive hCG test, hCG range 1.0 – 9.3 mIU/ml
hCG assay used is the Siemens Immulite hCG test with < 0.1% crossreactivity with LH. Standard deviation is abbreviated as SD.Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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becomes more evident in serum in perimenopause and
postmenopause [43,162,164,166,172-176].
The USA hCG Reference Service is a clinical reference serv-
ice specializing in unexplained hCG production and in
gestational trophoblastic diseases. Despite the 20+ publi-
cations in major medical journals on the normality of
positive serum hCG in perimenopause and postmeno-
pause women and in those having had bilateral oophorec-
tomy, physicians continue to be needlessly concerned,
considering gestational trophoblastic disease and cancer
as possible options. The USA hCG Reference Service has
investigated 319 cases with persistent low hCG results in
the absence of history gestational trophoblastic disease or
other malignancy (Table 5). These included 112 woman
producing hCG that was later proved to be of pituitary ori-
gin (Table 5). These were 43 woman postmenopause with
amenorrhea, ages 50 to 62, with mean serum regular hCG
level of 11 ± 6.2 ranging from 8 to 28 mIU/ml. There were
60 woman perimenopause with oligomenorrhea, ages 39
to 59, with mean serum regular hCG level of 9.8 ± 6.7
[172-176] ranging from 2 to 22 mIU/ml. Finally there
were 9 women of normal menstrual cycle age that had
received bilateral oophorectomy for cancer-related rea-
sons, putting them into amenorrhea, they had a mean
serum regular hCG level of 10 ± 7.2 mIU/ml ranging from
7 to 25 mIU/ml [172-176]. As shown in Table 5, of the
319 cases with persistent low hCG results, the concluding
diagnoses has ranged from pituitary hCG, non-gestational
malignancy, gestational trophoblastic neoplasm, quies-
cent gestational trophoblastic disease and false positive
hCG. As shown, in the USA hCG Reference Services expe-
rience, pituitary hCG is the prime cause of persistent low
hCG levels [176].
Medical centers throughout the world demand a serum
total hCG test prior to any surgery, prior to many x-ray
procedures and to certain drug protocols. The erroneous
assumption is made by medical centers id that a total hCG
test can only show pregnancy. If a woman is positive in
the hCG test she is referred to an obstetrician. Unfortu-
nately few obstetricians are aware of pituitary hCG. If a
women in oligomenorrhea or amenorrhea has a positive
pregnancy test prior to surgery it can mean multiple
months of delays and false alarms before pituitary hCG is
identified and the procedures are rescheduled. The USA
hCG Reference Services has consulted on 12 cases waiting
multiple years for kidney transplants. When the match
was found the procedures were cancelled due to positive
hCG tests. In each case multiple months passed before the
USA hCG Reference Service was contacted and normal
physiology pituitary hCG identified. The patients then
rejoined the waiting list once more for a kidney trans-
plant. There should be no requirement for an hCG test if
a woman is over 45 years old.
Perimenopause can be difficult to diagnose. The normal
symptom is oligomenorrhea. Is the hCG of pituitary ori-
gin? A recent article by Granowitz and colleagues [177]
shows that the presence of an elevated FSH levels of > 30
mIU/ml justifies the presence of peri- or postmenopause
and the presence of pituitary hCG. This is and evaluable
method for determining whether pituitary hCG is possi-
ble. The pituitary as the source of hCG can be confirmed
by placing subjects on a high estrogen oral contraceptive
pill for 3 weeks. It will suppress pituitary hCG and the
hCG will no longer be detectable [174-176].
hCG immunoassays
The discovery of monoclonal antibodies in 1975 was par-
amount to the development of modern immunometric
tests [9]. Modern two-antibody immunometric assays for
hCG arose in the early nineteen eighties; with them came
the concepts of antibody enzyme labeling and high sensi-
tivity fluorimetric and chemiluminescent detection assays
[10-14]. These mechanisms are the basis of the automated
tests used in all commercial laboratories today. The prin-
cipal of the immunometric test is one antibody (called the
capture antibody) binding one site on hCG and immobi-
lizing it and a second antibody labeled with enzyme tracer
(called a tracer antibody) binding a distant site on hCG
labeling the immobilize complex. The immobilized and
labeled  capture antibody-hcg-tracer antibody complex can
then be quantified, with the amount of tracer or tracer
enzyme products being directly proportional to the
amount of complex or concentration of hCG. The dual
antibody immunometric technologies are also the basis of
all modern physician's office point of care (POC) rapid
pregnancy tests and home use or over the counter (OTC)
rapid pregnancy tests with one antibody immobilized in
the result window on the nitrocellulose device and one
antibody mixing with the serum or urines and labeled
Table 5: The USA hCG Reference Service experience, 1997 – 2008 with 319 cases with persistent low positive hCG in the absence of 
pregnancy or history of gestational trophoblastic disease or other malignancy.
Source of hCG Menopause Ages > 50 Perimenopause Ages > 40 Menstrual Ages 18 – 40
Pituitary hCG 43 60 9
Non-trophoblastic neoplasm 0 2 9
Gestational trophoblastic neoplasm 0 2 10
False positive hCG test 1 8 82Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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with a blue or red dye as tracer. A positive result is indi-
cated by a line formed by the immobilized antibody-hCG-dye
antibody complex.
As discussed throughout this article there are multiple var-
iants of hCG in serum and urine in different pregnancy
and cancer conditions (Table 1) [14,27-34,41-43,48],
these may be invariably detected by different types and
different brands of hCG test. By definition there are today
2 clear classes of hCG immunoassay. Intact hCG assays
which may or may not detect all forms of dimer (hyperg-
lycosylated hCG, nicked hCG and regular hCG), and total
hCG tests which may or may not detect hCG dimer and its
free β-subunit (hCG free β, hyperglycosylated hCG free β,
nicked free β, free β-subunit missing the βCTP and β-sub-
unit core fragment). There are also three clear types of
hCG tests. There are professional laboratory quantitative
serum hCG tests (PRL tests), point of care or physicians
office qualitative serum and urine hCG tests (POC tests),
and home or over the counter qualitative hCG tests (OTC
tests).
Most PRL tests used today are total hCG assays. These
most commonly involve an antibody to the β-subunit
core structure (tertiary structure formed by β1–92) as
tracer antibody combined with an antibody to the βCTP
(β92–145) as capture antibody. This insures minimal rec-
ognition of LH, which lacks a βCTP. There are 2 major
limitations with assays using this antibody combination.
Antibodies to the natural βCTP commonly are dependent
upon the O-linked oligosaccharide structure on the natu-
ral βCTP, since this accounts for a major portion of the
molecular weight of this segment. Most assays using this
antibody configuration poorly detect hyperglycosylated
hCG, so critical for use in early pregnancy detection and
in choriocarcinoma management (Table 1), because the
immunoglobulin used is against the regular hCG βCTP.
While this combination usually detects nicked hCG it
does not detect hCG or free β missing the C-terminal seg-
ment. Some manufacturers have replaced the antibody to
the natural βCTP with an antibody to a βCTP synthetic
peptide, β131–145, with no oligosaccharide component.
An assay with using an antibody to the synthetic βCTP
does not distinguish regular hCG and hyperglycosylated
hCG. An alternative configuration used by one manufac-
turer involves 2 antibodies to different regions of the β-
subunit core structure. This rare combination permits
detection all 13 dimer and β-subunit variants (Figure 3).
We ask why doesn't every manufacturer try and optimize
their hCG assay to detect the 13 variants of hCG? Why do
some manufacturers sell a test that detects primarily regu-
lar hCG and poorly detect variants, yet claim there test to
be an optimal hCG test. While others sell tests that detect
the13 of 13 dimer and β-subunit variants claim nothing
more? As will become apparent from reading this article,
detection of 13 of 13 dimer and β-subunit variants is crit-
ical for using hCG as a pregnancy test, gestational tro-
phoblastic disease test and cancer test (Table 1)?
Unfortunately all variants of hCG are simply considered
as general hCG to physicians, they order hCG tests for
pregnancy, gestational trophoblastic disease and cancer
cases regardless of the specificity of the test used by the
laboratory. Laboratories usually order tests based on their
throughput, speed and cost. The problem arises with the
FDA, who regulate all hCG tests. Their guidelines are
entirely based on rather dated 1960s, 1970s and 1980s
information, under which hCG is one molecule and
detection of only regular hCG is required. There is no
requirement to detect hyperglycosylated hCG, even
though we now know today that it is the principal or sole
variant of hCG present in serum and urine in early preg-
nancy [40,42,43,45,46,79,178,179], and no requirement
to detect free β-subunit or its degradation derivatives (Fig-
ure 3), which we now know is the only form produced by
cancers. Modern hCG test do state that the test is only
approved for pregnancy detection and is not approved for
managing gestational trophoblastic diseases or cancer
applications (clinicians are not informed of this, it is
solely in a note included in the test ingredient box deliv-
ered to the laboratory), even though the use of these
application continue at every clinical laboratory, regard-
less of this limitation and regardless of which hCG test
their laboratory uses. In fact, no test is approved by the
FDA for gestational trophoblastic disease, Down syn-
drome screening, detecting failing pregnancies or cancer
testing. In many ways gestational trophoblastic disease
and cancer patients are left in the cold, with no manufac-
turer interest in producing an optimal test. The end result
of the outdated FDA rules is that manufacturers have no
interest and no financial benefit in updating or improving
the specificity of their assays. In our experience the only
tests made that is appropriate for all applications in the
Siemen's Immulite series (Immulite 1000, Immulite 2000
and Immulite 2500, same antibody mix but different plat-
forms designed for different throughput).
We examined the major hCG tests sold in the USA, those
accounting for > 1% of the USA market (Table 6). They are
all automated total hCG immunometric assays. Each
assay is sold in semi-automated formats for low through-
put centers, and high throughput fully automated formats
for intensive use laboratories. All tests are run from a com-
puterized platform. As shown in Table 6, all assays detect
regular hCG and all may or may not detect other hCG var-
iants. The Roche Elecsys series poorly detects anything
other than regular hCG and hCG free β, and the Siemens
Dimension (used to be Dade Dimension), like the Roche
assay, poorly detects hyperglycosylated molecules, so crit-
ical to pregnancy. Multiple tests, such as the Baxter Stratus,Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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Siemens AC180, Siemens Centaur and Beckman Access
and DXI all inappropriately detect hCG β-subunit (not
detected on equimolar basis with regular hCG) and hyper-
glycosylated hCG free β. The majority of tests do not
detect hCG or its free β-subunit missing the C-terminal
segment [79,179] (Table 6). Only one assay, that using
the 2 antibodies to the β-subunit core structure, detects all
pertinent standards. As such, only one assay is useful for
all pregnancy, gestational trophoblastic disease and can-
cer application, this is the Siemen's Immulite series (used
to be DPC Immulite series). It should be noted that the
author of this review, Laurence A. Cole PhD has no finan-
cial, consulting or other conflicts of interest with DPC or
Siemens. The finding that the Siemen's assay is the most
appropriate is strictly the result of blind unbiased testing
at multiple laboratories.
As shown in Table 7 most assays, with the exception of the
Siemen's Immulite series give widely varying results when
used for gestational trophoblastic disease and cancer
management. Looking, for instance, at a case of serous
ovarian cancer in Table 7 (15th cases from top), results var-
ied from 1 mIU/ml (Baxter Stratus) to 115 mIU/ml (Sie-
men's Immulite series) dependent on the assay being
used. In this case the patient was primarily producing
hyperglycosylated hCG free β missing the C-terminal seg-
ment which was only appropriately detected by the Sie-
men's Immulite series assays. Examining a partial mole
case (20th case from top), results varied from 9 mIU/ml
(Baxter Stratus), to 15 mIU/ml (Beckman Access), to 31
mIU/ml (Siemens ACS180), to 48 mIU/ml (Abbott
Axsym), and 235 mIU/ml (Siemen's Immulite series)
depending on the assay being used. hCG missing the C-
terminal segment was also produced in this case. As
shown in Table 7, almost every gestational trophoblastic
disease or cancer sample is measured with extreme varia-
bility. There is no guide given by laboratories to physi-
cians to indicate which test is used or its limitations.
Physicans just assume that the test used at the medical
center is good.
Similar specificity problems are seen with POC and OTC
assays (Table 8). Most POC tests are for some strange rea-
son intact hCG tests detecting dimer only. Due to the con-
figuration of the antibodies in these devices, they poorly
detect hyperglycosylated hCG (Table 8) [48]. Similarly,
with one exception, manufacturers of OTC tests make
devices which poorly detect hyperglycosylated hCG
(Table 8). The one exception is the Church and Dwight
First Response and Answer devices that equally detect reg-
ular hCG, hyperglycosylated hCG and free β-subunit
[180]. It is astonishing that other manufacturers of POC
and OTC devices market devices that poorly detect hyper-
glycosylated hCG since measurement of this molecule is
critical to early pregnancy detection. How can these be
called pregnancy tests? Once more the blame is placed on
the FDA and their very out of date guidelines and the
absence of a requirement to detect anything other than
regular hCG. They basically permit all manufacturers,
regardless of what they produce, to label their devices sim-
ilarly "greater than 99% accurate." This leads to much
misinterpretation and confusion.
Table 6: Ability of the most commonly used automated professional laboratory immunometric hCG tests (all tests used by > 1% of 
USA market) to measure hCG variants [83,84].
Standard Abbott 
AxSym
Baxter 
Stratus
Siemens 
ACS180
Siemens 
Centaur
Beckman 
Access
Ortho 
Vitros Eci
Tosoh A1A Roche 
Elecsys
Siemens 
Immulite
R e g u l a r  h C G ++++++ + ++
Hyperglycos
ylated hCG
++++++ +?+
Nicked hCG + + + + + + + ? +
Nicked 
hyperglycosy
lated hCG
++++++ +?+
Nicked hCG 
missing 
βCTP
------ X -+
Free β +????+ + + +
Hyperglycos
ylated free β
+????+ + ?+
Urine, β-
subunit core 
fragment
------ - -+
Most commercial tests were evaluated at multiple laboratories. Antigens appropriately recognized by assays (detection of standard varies from 
calibrated concentration by no more than 25%) are indicated by +. Those invariably detected in a specific assay (result more than 25% different 
from calibrated concentration) are indicated by ?, and those not detected at all are indicted by -.Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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We sadly conclude that the field of hCG assays is full of
confusion. This is in large part due to inappropriate FDA
regulations. It is important for test and platform purchas-
ers to be weary of these limitations and to choose a test
with consideration of all possible applications. It seems
that only with laboratories exclusively choosing broad
specificity tests like the Siemen's Immulite (a small part of
the hCG market in the USA) and the Church and Dwight's
First Response or Answer (OTC tests, better than all avail-
able POC tests), that the market will change and manufac-
turer's will be economically forced to produce better
quality products. Some centers, like the Charing Cross
Hospital, Gestational Trophoblastic Disease Center, in
London, UK have little trust in any automated hCG test
for their gestational trophoblastic disease and cancer
applications [181]. They only trust results from their "in
house" hCG β-subunit competitive radioimmunoassay.
At the USA hCG Reference Service we will only use the Sie-
mens Immulite. We are referred pregnancy and cancer
patients with erroneous hCG results. All too often we are
referred cases that have received needless therapy due to
faulty hCG results, or missed therapy due to missed recur-
rence of disease. The specificity problem lingers on year
after year, it must be addressed, and can probably only be
resolved by the FDA.
Table 7: Ability of automated laboratory immunometric hCG tests to detect hCG variants in 30 serum samples from gestational 
trophoblastic disease and cancer patients.
Diagnosis Abbott AxSym hCGβ 
mIU/ml (% median)
Baxter Stratus hCG 
mIU/ml (% median)
Siemens ACS180 hCG 
mIU/ml (% median)
Beckman Access 
hCGβ mIU/ml 
(% median)
Siemens Immulite 
hCG mIU/ml 
(% median)
Partial mole 5 (112%) 2 (53%) 3 (72%) 6 (127%) 4 (88%)
Choriocarcinoma 7 (110%) 3 (49%) 5 (71%) 9 (133%) 6 (90%)
Partial mole 10 (107%) 7 (73%) 7 (70%) 10 (108%) 9 (93%)
Complete mole 16 (117%) 12 (89%) 14 (104%) 15 (115%) 13 (96%)
Complete mole 18 (132%) 6 (42%) 14 (104%) 18 (131%) 11 (84%)
Complete mole 16 (119%) 7 (53%) 11 (81%) 16 (119%) 11 (80%)
Partial mole 26 (110%) 15 (62%) 22 (95%) 25 (105%) 19 (81%)
Complete mole 40 (133%) 15 (51%) 30 (100%) 36 (119%) 29 (96%)
Ovarian 
dysgerminoma
85 (138%) 34 (55%) 63 (102%) 72 (118%) 47 (76%)
Complete mole 91 (116%) 56 (71%) 88 (112%) 90 (114%) 69 (88%)
Testicular germ cell 102 (124%) 60 (73%) 88 (107%) 92 (112%) 78 (95%)
Partial mole 88 (104%) 59 (70%) 81 (96%) 91 (108%) 81 (96%)
Choriocarcinoma 126 (126%) 78 (78%) 102 (102%) 128 (128%) 101 (101%)
Partial mole 153 (143%) 69 (64%) 103 (97%) 121 (114%) 110 (103%)
Serous Ovarian 
Cancer
70 (64%) 1 (0.9%) 65 (59%) 67 (61%) 115 (105%)
Complete mole 198 (130%) 106 (70%) 159 (104%) 176 (116%) 146 (96%)
Partial mole 245 (124%) 138 (70%) 188 (95%) 214 (109%) 206 (105%)
Ovarian 
dysgerminoma
221 (99%) 64 (29%) 226 (101%) 242 (108%) 184 (82%)
Partial mole 291 (127%) 173 (75%) 260 (113%) 256 (111%) 224 (97%)
Partial mole 48 (20%) 9 (3.8%) 31 (13%) 15 (6.3%) 235 (99%)
Complete mole 607 (108%) 453 (81%) 603 (108%) 614 (110%) 560 (100%)
Partial mole 668 (115%) 475 (82%) 725 (124%) 782 (134%) 555 (95%)
Choriocarcinoma 603 (93%) 687 (107%) 955 (148%) 842 (131%) 550 (85%)
Complete mole 717 (94%) 759 (99%) 999 (131%) 924 (121%) 769 (101%)
Complete mole 704 (91%) 666 (86%) 943 (122%) 925 (97%) 751 (119%)
Complete mole 1,109 (131%) 655 (77%) 904 (107%) 972 (115%) 827 (98%)
Partial mole 1,027 (112%) 891 (98%) 1,230 (135%) 1,094 (120%) 930 (102%)
Complete mole 9576 (69%) 7995 (58%) 6378 (46%) 7437 (54%) 16320 (118%)
Complete mole 21515 (42%) 16305 (32%) 17070 (33%) 19005 (37%) 52350 (102%)
Choriocarcinoma 13640 (102%) 12145 (91%) 12970 (97%) 13310 (100%) 14720 (111%)
Varies by > 25% 
median
11 of 30 results 21 of 30 results 10 of 30 results 10 of 30 results 0 results
Blindly determined results are presented, as are percents variation of the median result. The proportion of samples using each tests that varies by > 
25% of median results is determined.
a hCG missing βCTP, median determined with assays detecting βCTP (Siemens Immulite, Siemens Dimension and hCGβ radioimmoassay)Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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hCG standards
The 3rd International Standard (IS, WHO code 75/537)
and 4th IS (WHO code 75/589) have been widely used
throughout the world for calibrating and testing all PRL,
OTC and POC hCG assays for over 20 years [182]. They
are both prepared form very large urine extracts prepared
by Canfield and Birken at Columbia University, New
York, under contract with WHO to produce hCG-related
standards. They are calibrated in biological units, interna-
tional units per liter (IU/L), somewhat arbitrary and
meaningless for their principal use, immunoassay. As pre-
pared, 1 μg of pure urine hCG is equivalent to 9.3 IU or a
vial of 40 IU contains 4.3 μg of pure urine hCG [182].
Sequence analysis shows that these pure hCG prepara-
tions contain 9% nicked hCG, they also contain varying
levels of hCG free β and hyperglycosylated hCG free β and
significant proportions (15–18%) of hyperglycosylated
hCG [18] and β-subunit core fragment [14].
Multiple articles complain about the limitations of these
standards, that two tests may give different results using
the standards, depending upon whether they detect
nicked hCG or hyperglycosylated hCG [14,179,183].
Other authors find problems with the urine origin of the
standards and the differences in urine and serum hCG
charge variants [184]. A new purer set of standards was
needed.
Standards have also produced by WHO for free β-subunit
and free α-subunit. These standards are also calibrated in
arbitrary international units where 1 IU/L is 1 μg/L. These
standards are somewhat incompatible with hCG stand-
ards, since 1 IU of free β represent 0.045 nmol of free β,
and 1 IU of hCG represents 0.0029 nmol of hCG. As such,
1 IU of free β contains 15.5-fold more β-subunit than 1 IU
of hCG.
New standards have now been prepared using molar units
so that measurement of hCG and degradations products
can be completely compatible [185]. Efforts were directed
at purifyng hCG further to rid the preparation of nicked
molecules and free subunits [185]. The new hCG standard
is the 1st Reference Reagent (WHO code 99/688). Stand-
ards were also prepared for the separate β-subunit (WHO
code 99/650), separate α-subunit (WHO code 99/720),
nicked hCG (WHO code 99/642), nicked β-subunit
(WHO code 99/692) and β-subunit core fragment (WHO
code 99/708). All of the new standards are strictly cali-
brated on a molar basis. Physicians throughout the world,
however, are very used to IU/L and to all the different ele-
vated, low and high problem values in IU/L. Unfortu-
nately physicians have generally rejected moving to the
more logical molar units. With this rejection, laboratories
and manufacturers have unfortunately had to refrain from
adopting these new standards.
Problems are noted with these new standards. Firstly,
while a standard is available for nicked hCG and nicked β-
subunit, two standards with little or no clinical applica-
tion, no standard was made available by WHO for hyper-
glycosylated hCG a key placental molecules with
numerous clinical applications. We are told that this is
Table 8: Utility of POC and OTC urine hCG testing devises to detect hCG variants. of β-core fragment by urine POC pregnancy 
devices.
Device Regular hCG Hyperglycosylated hCG hCG Free β Hyperglycosylated hCG free ββ -subunit core fragment
A. Point of care devices
Beckman Icon 25 + ? - - -
Beckman Icon 20 + ? - - -
Beckman Icon II + ? - - -
Inverness Acceava + ? ? ? -
Inverness Clearview + ? ? ? -
Mainline Confirms + ? - - -
Quidel Quick Vue + ? - - -
Quidel Instant Vue + ? - - -
B > Over the counter devices
Clear Blue Easy + ? + ? -
Clear Blue Easy Digital + ? + ? -
E.P.T. + ? + ? -
E.P.T. Digital + ? + ? -
First Response + - + + -
First Response Digital + - + + -
Devices were tested with a sample containing 2.5 μg/L (100 IU/L) pure β-core fragment and no other form of hCG. Antigens appropriately 
recognized by assays (detection of standard varies from calibrated concentration by no more than 25%) are indicated by +. Those invariably 
detected in a specific assay (result more than 50% different from calibrated concentration) are indicated by ?, and those not detected at all are 
indicted by -.Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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due to the absence of a reliable source of hyperglyco-
sylated hCG. As shown in Table 2, hyperglycosylated hCG
is very prominent in the first 2–3 weeks following implan-
tation of pregnancy, but become a relatively minor com-
ponent of serum and urine total hCG thereafter. This has
made production of a hyperglycosylated hCG standard
difficult, especially considering that urine hCG is collected
commercially for extractions (like that used by WHO)
during the time of the regular hCG peak or at 7 to 12
weeks of pregnancy. Serum and urine contain a hypergly-
cosylated hCG free β-subunit in cancer cases and a hyper-
glycosylated free α-subunit during pregnancy. The
standards presented by WHO are a separated hCG dimer
α-subunit and a separated hCG dimer β-subunit. These
may not be optimal for a free α-subunit or hyperglyco-
sylated hCG free β cancer test and may not match optimal
specificity tests. New standards are urgently needed for
hyperglycosylated hCG, free α-subunit and hyperglyco-
sylated hCG free β assays.
False positive and false negative hCG assays
In an immunometric assay a complex is formed, capture
antibody-hCG-tracer antibody. The two antibodies used may
be goat, sheep or rabbit polyclonal antibodies or mouse,
goat or sheep monoclonal antibodies. Humans exten-
sively exposed to animals or certain animal byproducts
can develop human antibodies against animal antibodies
(HAAA), whether immunoglobulins A, E, G or M. In addi-
tion, humans naturally generate human anti-human
immunoglobulin antibodies that can cross-react with and
bind animal antibodies. These are called heterophilic
antibodies. Humans with recent exposure to mononucle-
osis can be prone to develop HAAAs and those with IgA
deficiency syndrome often have false positive assay prob-
lems due to heterophilic antibodies [186]. Each human
antibody is bivalent so if an HAAA or heterophilic anti-
body is present in a person's serum it can bind and link
together the immobilized and tracer antibodies making a
capture antibody-heterophilic antibody-tracer antibody com-
plex or a capture antibody-HAAA-tracer antibody complex.
Either way it leads to positive test results. These positive
results due to sandwiched of antibodies with HAAA or
heterophilic antibodies and not hCG variants are false
positive hCG test results. A positive test in the absence of
pregnancy has led to many women being wrongly diag-
nosed with cancer, to a lot of needless surgery and chem-
otherapy, and to a lot of confusion and misunderstanding
[187-192].
To avoid false positive tests, manufacturers incorporate
animal serum and excess non-specific animal antibodies
into all their test ingredients. An excess of non-specific
antibodies overwhelming binds and eliminates the inter-
ference of heterophilic antibodies and HAAA in human
serum samples.
False positive hCG tests were a big problem between 1999
and 2002, when hundreds of women were wrongly
assumed to have choriocarcinoma or cancer (textbooks
suggested these diagnoses, oncologist taught these diag-
noses when hCG was positive in the absence of preg-
nancy) because of HAAA or heterophilic antibodies and
false positive tests [187-191]. Some had history of gesta-
tional trophoblastic disease or other malignancy; others
had no history and were simply misdiagnosed with cancer
on the basis of a positive hCG test in the absence of preg-
nancy (oncology teachings at this time). It was this false
positive issue and the resulting chaos that led to the need
for a specialized hCG assay service and to the start of the
USA hCG Reference Service in 1997 [187]. The major
problem at this time was the Abbott AxSym hCG test, the
most commonly used test in the USA during this period.
This test had animal serum as a protector for HAAA or het-
erophilic antibodies in the diluent but not in the antibody
components [43]. As such, when serum was tested undi-
luted (with no diluent) it led to false positive test results.
There were multiple multi-million dollar law suits against
Abbott Diagnostics Inc. from young women having false
positive hCG test and needless hysterectomies and multi-
ple chemotherapy regimens for assumed cancer or
assumed gestational trophoblastic disease. There was also
a large class action lawsuit from those who underwent
cancer chemotherapy. With the multiple lawsuits profes-
sional medical societies wrote warning notes to their
members about false positive hCG tests. At the same time,
Abbott appropriately and quickly fixed their test. We have
not heard about an Abbott AxSym hCG false positive
patient since this time.
In recent years the USA hCG Reference Service has been
referred just 5–6 false positive serum hCG cases each year,
mostly from people being tested with a wide variety of dif-
ferent tests (Beckman Access, Bechman DXI, Baxter Stra-
tus, Ortho Vitros Eci, Roche Elecsys, Tosoh AIA, Siemens
Centaur, Siemens ACS180, Siemens Immulite and multi-
ple serum POC tests. It appears that every manufacturer's
test in extreme circumstances can give a false positive
result. With the suits and widespread publicity most phy-
sicians became very aware of the hCG false positive prob-
lem. It is rare today for the USA hCG References Service to
be consulted about a false positive case involving needless
hysterectomy or chemotherapy for assumed gestational
trophoblastic disease. Occasionally the reference service
proves false positive hCG in a case undergoing therapy for
gestational trophoblastic disease, a very confusing situa-
tion.
There are multiple studies that can be performed in the
laboratory that identify false positive hCG. The first is to
show the absence of hCG in the urine. Unfortunately, fed-
eral drug administration rules limit POC urine tests to 20Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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mIU/ml sensitivity. Available tests range from 20 to 50
mIU/ml sensitivity. These are the only urine hCG tests
offered in America. Urine hCG tends to vary from twice
serum concentration down to one tenth serum concentra-
tion, dependent upon liquid intake and diuresis. As such,
these tests may only be meaningful if serum hCG is over
150 mIU/ml. There is absolutely no reason why urine can-
not be tested on the same platforms as are used for testing
serum hCG, giving a meaningful urine result of sensitivity
as low as 1 mIU/ml [193]. Urine has been shown to work
appropriately for measurement of hCG on multiple
immunoassay platforms, on the Siemens Immulite [43],
Abbott AxSym [194], Siemens Centaur [195] and Roche
Elecsys [196]. A second useful way of identifying a false
positive serum hCG result is to send the serum to 2 other
laboratories using different commercial assays. If the assay
results vary greatly, or are negative in one or both alterna-
tive tests, then false positive hCG can be presumed.
False negative problems occur with hCG tests. False nega-
tive errors can occur in cases with levels of hCG above
500,000 mIU/ml in a "Hook Effect" [14,197]. Since most
hCG test are limited in sensitivity to the pregnancy hCG
range (at peak median hCG level is 128,300 mIU/ml) the
Hook Effect can falsely show very low hCG results or false
negative results (i.e. 1 – 100 mIU/ml) when an extremely
high hCG concentration is present due to consumption of
all (capture and tracer antibody) antibody binding sites
on both antibodies, permitting few or no sandwiches
[14,197]. In pregnancy, hCG rarely exceed 200,000 mIU/
ml, but in complete hydatidiform mole hCG and chorio-
carcinoma cases hCG can be as high as 3,704,085 mIU/
ml. If a patient has an MRI or ultrasound indicating hyda-
tidiform mole or choriocarcinoma and hCG is reported as
negative or < 100 mIU/ml then a Hook Effect needs to be
assumed and hCG testing repeated using 1/1000 diluted
serum. Physicians should inform laboratories of the need
for high dilution when testing new hydatidiform mole
and choriocarcinoma cases. Laboratories needs to be
informed of need for 1/1000 serum dilution to avoid
Hook Effect false negative problem.
False negative problems also occur with OTC and POC
pregnancy tests. Both type of tests make FDA approved
claims like "greater than 99% accuracy" and "use as early
as the day of missing menstrual period" yet may only
detect pregnancy in a proportion of individuals at the
time of missing the menstrual period [178,180,198]. A
negative test at the time of missing menses combined with
the advertisement "greater than 99% accuracy" may lead
to an erroneous false negative conclusion that one is not
pregnant. A person may then avoid pregnancy prepara-
tions, continue to consume alcohol and fetotoxic medica-
tions. Then the person may find out one month later that
she truly is pregnant. The pregnancy may a lead low birth
weight or preterm pregnancy or possible fetal alcohol syn-
drome pregnancy. This would all be a consequence of a
false negative OTC or POC pregnancy test, due to poor
sensitivity or poor specificity.
Immunoassay applications
Numerous publication in the past 10 years describe new
applications for total hCG tests and for new assays meas-
uring hyperglycosylated hCG alone and hyperglyco-
sylated hCG free β alone.
Regular hCG and pregnancy testing
The prime use of all hCG tests and the only FDA approved
use of hCG is pregnancy detection. Hyperglycosylated
hCG tests have been 510(k) approved by the FDA as a reg-
ular hCG alternative or as a pregnancy test, hCG free β has
been similarly 510(k) pregnancy test approved. Total and
intact hCG PRL, POC and OTC tests are used for screening
for pregnancy in women who are eager to achieve preg-
nancy and by those eager to exclude pregnancy after hav-
ing unprotected intercourse. Possible the biggest use of
the hCG test today is the nationwide checking of all
women, all ages, for any possibility of pregnancy prior to
surgery, prior to medical procedures or prior to X-rays.
Quantitative urine hCG tests are now used as part of all
profession sports to detect administration of hCG in ath-
letes as a promoter of androgens or anabolic steroids.
As shown in Table 2, serum hCG in early pregnancy is pri-
marily hyperglycosylated hCG [43,45,46,73,178]. In the
first few week of pregnancy, mean proportions of hyperg-
lycosylated hCG are higher in urine (3rd, 4th, 5th and 6th
week of gestation, mean hyperglycosylated hCG 92%,
68%, 50% and 25% of total hCG) than in serum samples
(3rd, 4th and 5th week of gestation, hyperglycosylated hCG
89%, 49%, 36% and 21% of total hCG)
[43,45,46,73,178]. Most people are first tested or first test
themselves for pregnancy during this early pregnancy
period. Realistically, if an hCG test is to be considered a
real pregnancy test it needs to detect regular hCG and
hyperglycosylated hCG equally. This is not true with at
least 2 major immunoassay platforms, the Siemens
Dimension and the Roche Elecsys (Table 6). It is also not
true with any POC test as described in Table 9, and with
most OTC tests (Table 8).
hCG changes in nature as pregnancy progresses, becom-
ing primarily regular hCG with hyperglycosylated hCG
constituting a minor component of hCG (< 2% of total
hCG) in the second and third trimesters of pregnancy
(Table 2). In urine samples, β-core fragment predomi-
nates as the principal variant of hCG from 7 weeks preg-
nancy until term [14]. No OTC or POC test detects β-core
fragment, they rely on detecting regular hCG. Free β-sub-
unit is also most evident in early pregnancy (Table 1),Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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becoming an extremely minor component of total hCG
during the bulk of pregnancy (< 1% of total hCG).
We question when can all pregnancy tests be used to
definitively detect or exclude pregnancy? PRL serum hCG
tests have published sensitivities of 5, 2 or 1 mIU/ml.
Urine and serum POC test have published sensitivities of
50, 25 and 20 mIU/ml and urine OTC tests have pub-
lished sensitivities of 50, 20 and 6.3 mIU/ml [46,48,179].
On the day of missing menses the median hCG concentra-
tion in serum is 239 mIU/ml and in a spot urine (any time
of day, no adjustment for creatinine) is 49 mIU/ml
[42,180]. The range of hCG concentrations varies
immensely at this time, serum hCG varies from < 1 to
3,780 mIU/ml and urine hCG from < 1 to 2,132 mIU/ml,
this is because of great variation in timing of implantation
of pregnancy, which can occur between the 16th and the
30th days of the menstrual cycle [201-203]. If a pregnancy
implants early (due to early ovulation, fertilization and
implantation) on the 16th day of the menstrual cycle, for
instance, with rapid 48 hour doubling of hCG concentra-
tions the serum and urine values can be in thousand of
mIU/ml at the time of missing menses. If, in contrast, the
embryo implants late (due to late ovulation, fertilization
and implantation) the hCG results can be very low at the
time of missing menses in serum and urine. Wilcox and
colleagues suggested that implantation can occur as late as
11 days after the predicted date of missing menses
[202,203]. This seems hard to believe. New studies have
found error with this data and show that implantation
occurs only as late as the day of missing menses [201].
Since hCG cannot be detected until implantation has
occurred [201-203], hCG levels in serum and urine can be
< 1 mIU/ml or undetectable on the day of missing men-
ses. Considering all this data, and the concentration of
hCG, no assay can 100% detect or exclude pregnancy until
2–3 days after the day of missing menses.
A further complication of pregnancy detection is that 25%
of pregnancies are biochemical pregnancies or early preg-
nancy losses [43,203-205]. These are pregnancies which
fail initial stages of implantation leading to rapid failure.
They cause, however, a brief incline of serum and urine
hCG concentrations which may cause a pregnancy test to
misleadingly be positive at the time of missing menses.
This transient hCG can in some cases extend to 4 day after
the time of missing menses [43,203-205]. This is a further
reason for not performing a pregnancy test as early at the
time of missing menses. If the pregnancy test is positive it
may be a biochemical pregnancy or early pregnancy loss,
and if it is negative it may be nothing more than a false
negative due to the sensitivity of the test or a true negative
and misleading negative due to a late implanting preg-
nancy. Unfortunately, the literature included with PRL
serum tests indicates use as early as 4 weeks since the last
menses, and the literature included with POC tests indi-
cates uses as early as the time of missing menses. OTC tests
are now competing with each other to determine preg-
nancy earlier and earlier, with FDA approved claims like
"use as early as 4 days prior to the day of missing menses."
All these test, whether professional laboratory, OTC or
POC are just vague indications at this time, and should
not be considered definitive. In our experience, from pub-
lished data, a firm pregnancy test result, definitely preg-
Table 9: USA hCG Reference Service experience, concentration of hCG, hyperglycosylated hCG and hyperglycosylated hCG free β 
(HhCG β) in serum samples in gestational trophoblastic diseases and non-gestational malignancies.
Source n Total hCG mIU/ml median 
(range)
hCG-H mIU/ml molar1 % total 
hCG ± SD?
HhCGβ mIU/ml molar1 % total 
hCG ± SD
Complete hydatidiform mole
(prior to evacuation)
30 192,995
(24160 – 3704084)
4.9 ± 2.1% 7.1 ± 20%3
Partial hydatidiform mole
(prior to evacuation)
21 48,900
(11600 – 220114)
3.6 ± 1.7% 5.8 ± 22%3
Invasive mole, recurrent mole
(at commencement of therapy)
72 869
(24 – 30255)
30 ± 35% 7.7 ± 11%
PSTT
(at time of diagnosis)2
21 30
(1 – 231)
7.1 ± 13% 61 ± 21%
Highly invasive Choriocarcinoma
> 50% hyperglycosylated hCG2
17 45,350
(3,020 – 596,600)
98 ± 5% 7.8 ± 8.4%
Invasive Choriocarcionoma
< 50% hyperglycosylated hCG
44 4,258
(108 – 10,245)
32 ± 11% 6.4 ± 7.5%
Quiescent GTD
(at time of diagnosis)2
93 22
(1 – 212)
0.10% ± 0.72% 2.7 ± 8.4%
Other gynecologic malignancies
(at time of diagnosis)2
14 33
(0.5 – 474)
0.55 ± 1.3% 91 ± 11%
SD is standard deviation. Choriocarcinoma cases are those with and without histology (GTN).
1Values are measured in molar units and converted to equivalents of hCG, assuming that 1 ng/ml hCG is 11 mIU/ml (using hCG 1st RR standard).
2As measured by USA hCG Reference Service, indicated diagnosis confirmed at biopsy by referring center
3 As published by Van Trommel et al. (45).Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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nant or definitely not pregnant result cannot be
determined until approximately 5 days after missing men-
ses or to approximately 5 weeks of gestation.
Hyperglycosylated hCG immunoassays for pregnancy 
testing, pregnancy failure and trisomy pregnancy
The hyperglycosylated hCG assay has been variably avail-
able between 2000 and 2008. In 1999 antibody B152 was
generated which specifically detects hyperglycosylated
hCG and has no measurable binding activity with regular
hCG [99]. The assay and applications were licensed to
Quest Diagnostics Inc, they own all rights to the antibody.
In 2003 the B152 assay was established on the Nichols
Diagnostics Inc. Nichols Advantage platform [200]. It was
used for Down syndrome screening at Quest Diagnostics.
In 2006 Nichols Diagnostics closed down. Since this time
Quest Diagnostists has made a microtiter plate assay avail-
able for Down syndrome screening through their clinical
laboratory service, They have also offered their hyperglyc-
osylated hCG test for gestational trophoblastic disease
and pregnancy applications. It is Quest Diagnostics order
code 4823. Quest plans to market the test through a major
manufacturer as soon as possible. Availability of the
hyperglycosylated hCG test for research labs has been var-
iable, numerous investigators used the Nichols Diagnos-
tics assay and now await the commercial release of a new
assay. B152 is the only antibody successfully generated to
date. It is a low affinity antibody preventing it's used in
OTC and POC tests. B152 is an antibody against hyperg-
lycosylated hCG dimer, B152 assays poorly detects the
hyperglycosylated hCG free β. Multiple centers have tried
to make a hyperglycosylated hCG specific antibody with-
out success. The βCTP and its hyperglycosylated oligosac-
charides are seemingly weak or awkward immunogens.
Hopefully, new hyperglycosylated hCG-specific antibod-
ies will be generated in the near future along with new
commercial assays,
Multiple studies suggest that hyperglycosylated hCG may
be used as an improved test for early pregnancy testing in
IVF settings [42,45,73,180]. In IVF procedures, regular
hCG is administered to promote poly-ovulation. It takes
2–3 weeks after embryo transfer for the administered hCG
to leave the system. It is only after the exogenous hCG has
departed the system that endogenous hCG can be meas-
ured to demonstrate pregnancy. Hyperglycosylated hCG
is the principal form of hCG produced in the first weeks
of pregnancy (Table 2). If hyperglycosylated hCG is used
as a pregnancy test it will only detect endogenous hyperg-
lycosylated hCG independent of administered regular
hCG, permitting pregnancy detection as soon as implan-
tation has occurred or at 3–4 days after embryo transfer. A
hyperglycosylated hCG pregnancy test also poorly detects
or fails to detect biochemical pregnancies or early preg-
nancy losses. As published, these pregnancies are seem-
ingly a consequence of insufficient production of
hyperglycosylated hCG [45]. These very transient preg-
nancies are a source of 3–5 days false hope among women
eager to achieve to achieve pregnancy. They are poorly or
not detected by hyperglycosylated hCG, and are best not
detected. Hyperglycosylated hCG is a better pregnancy test
than regular hCG for assisted reproductive technology
applications. As described below, hyperglycosylated hCG
may also show advantages in assessing outcome of preg-
nancy, failing pregnancy or term pregnancy [45].
The hCG doubling test has been widely used as an indica-
tion of pregnancy failure, miscarriage or ectopic preg-
nancy between 4 and 7 weeks of gestation [206-211]. The
hCG doubling test involves measuring serum hCG once
and them measuring hCG 48 hours later and determining
if serum concentration has doubled during this 48 hour
period. It is used in individuals with worry of miscarriage
due to older age for pregnancy (> 40), previous history of
miscarriage or infertility problems. It is also used in the
emergency room along with ultrasound to identify ectopic
pregnancy. Ultrasound reportedly is 84% sensitive for
detecting ectopic pregnancy [212,213]. The hCG doubling
test is then used to confirm the presence of ectopic preg-
nancy. After the hCG doubling test confirmation meth-
otrexate is used to destroy and abort the ectopic pregnancy
or a salpingectomy is performed.
The USA hCG Reference Service reference service hears
often from women having the hCG doubling test. For
instance: "my hCG did not double in 48 hours, does that
mean I am definitely have a failing pregnancy?" "I had a
salpingectomy for ectopic pregnancy, pathology showed
no pregnancy, can you explain why?" The hCG doubling
test is grossly inefficient with a very high false positive rate
[214,215]. In our experience with the Infertility Clinic at
University of New Mexico Medical Center, the test
detected 77% of failures at a 36% false positive rate, indi-
cating a predictive value positive of only 25% or 1 in 4 for
failures [216]. Considering the incidence of miscarriages
and ectopic pregnancy in the USA, 18% of pregnancies (1
in 5.5 pregnancies), the hCG doubling test is only a frac-
tion better than guesswork [216].
The concept of the hCG doubling test arose in the 1980s
and was shown useful at this time. At this time hCG tests
were hCGβ RIA which equally detected regular hCG,
hyperglycosylated hCG, hCG minus βCTP and hCG free
β-subunit. It is our understanding that hyperglycosylated
hCG and hCG free β-subunit were the principal parts of
the test [216]. Today, with modern automated hCG test
that poorly detect hyperglycosylated hCG and free β-sub-
unit the hCG doubling test has become less appropriate.
Yet there has been no reduction in use of this test by phy-
sicians. The USA hCG Reference Service considers this testReproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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a very vague indication (1 in 4 detection of 1 in 5.5 preg-
nancy detections). When people call with concern about
results we tell them that it is just a very vague indication.
Multiple studies by different groups suggest that measur-
ing free β-subunit alone and hyperglycosylated hCG alone
are much more accurate predictions test of pregnancy fail-
ures [43,45,73,151,217]. Hyperglycosylated hCG can be
used on the day of implantation to identify a term preg-
nancy versus failing pregnancy with 100% accuracy [43].
This test can be used at 4 weeks to 7 weeks gestation to
detect 73% failures at 2.9% false positive rate, or has a pre-
dictive value positive of 82% [151]. Hopefully this new
single blood draw test can replace the hCG doubling test
is detecting miscarrying and ectopic pregnancies.
Amniocentesis is an absolute test for pregnancy cytogenet-
ics permitting identification of trisomy 21 or Down syn-
drome (the most common genetic abnormality) and
other aneoploidies, monosomies and trisomies of preg-
nancy. Amniocentesis, however, is performed from 14 to
26 weeks of gestation, leading to late terminations of preg-
nancy for those opting to abort. Pregnancy termination is
a complication of 1 in 200 to 1 in 400 amniocentesis pro-
cedures (dependent on center performing procedure and
patient complications). Cytogenetics can be determined
earlier in gestation, 9–11 weeks gestation, using chorionic
villous sampling. The parental risk for termination in cho-
rionic villous sampling is about 2-fold higher, 1 in 100 to
1 in 200 failures. Risk for Down syndrome pregnancies
rises greatly as age advances, occurring in 1 in 1000 preg-
nancy below age 30 to 1 in 105 pregnancies by age 40
[218], yet most individuals attain pregnancy prior to age
30, so that more Down syndrome fetus occur in pregnant
woman younger than age 30. In women younger that 30
with a 1 in 1000 Down syndrome risk it is statistically
more appropriate to not take the higher risks of amnio-
centesis or chorionic villous sampling to determine their
cytogenetic outcomes. New test were needed or new sup-
plemental tests were needed to select younger women
warranting the risks of cytogenetic screening.
In 1984 Chard and colleagues showed that α-fetoprotein
was a limited indicator of Down syndrome pregnancy
[219]. In 1987 Bogart and colleagues [41] discovered that
Down syndrome pregnancies were associated with 2-fold
higher pregnancy hCG levels in the second trimester of
pregnancy. Then one year later Wald and colleagues
showed that unconjugated estriol was also a useful marker
[220]. This led to the use of the combination of the three
markers, hCG, α-fetoprotein and unconjugated estriol
together as a triple test for predicting those at high risk for
Down syndrome pregnancy, or those warranting the risk
of amniocentesis, in the second trimester of pregnancy.
Improvement came in the sensitivity for detecting Down
syndrome pregnancy, with the addition of inhibin A as a
fourth marker in a quadruple test [221]. Great improve-
ment came using hyperglycosylated hCG in place of regu-
lar hCG in the detection of Down syndrome [52]. The
hyperglycosylated hCG-based Down syndrome screening
is now run routine at Quest Diagnostic Inc.
In the late 1990s serum markers were first used for first tri-
mester Down syndrome screening, with chorionic villous
sampling used to determine cytogenetics in those indi-
cated at risk. Use of hCG free β-subunit was found prefer-
able to regular hCG [222]. In 1992 Nicolaides and
colleagues found that fetal nuchal translucency as meas-
ured with ultrasound was a powerful indicator of Down
syndrome pregnancy [223]. The combination of ultra-
sound nuchal translucency with laboratory measurement
of free β-subunit and pregnancy-associated plasma pro-
tein-A (PAPP-A) became a standard combination of tests
to assess risk for Down Syndrome fetus. In 2003, hyperg-
lycosylated hCG was used to replace free β-subunit and to
improve the sensitivity of the test combination [224].
Today, the nuchal translucency combinations with PAPP-
A and free β-subunit and PAPP-A and hyperglycosylated
hCG are the principal predictors for Down syndrome
screening risk used throughout the world. While a positive
test with this combination of markers is the optimal pre-
diction, it still only indicates approximately 1 in 20
chance of having a Down syndrome fetus, and the need
for chorionic villous sampling or amniocentesis to give a
definitive prediction.
Total hCG and hyperglycosylated hCG immunoassays for 
gestational trophoblastic diseases
A complete hydatidiform mole is the product of an empty
egg (no haploid set) and an androgenic fertilization and
is entirely composed of cysts of villous placental tissue
(diploid) [225,226]. A partial hydatidiform mole has an
androgenic or dispermic pregnancy with an inactive hap-
loid egg leading to a combination of cysts, normal tro-
phoblast elements and fetal elements (triploid) [227]. The
two types of molar gestations are easily differentiated
cytogenetically [228]. The occurrence of hydatidiform
moles in the United States is approximately 1 in 900 preg-
nancies [229]. Symptoms of a persistent or invasive mole
may follow a pathologically identified mole. They may
also follow what was recorded as a spontaneous abortion,
without cytogenetics or pathology [230,231].
Patients with a hydatidiform mole commonly present
with unusually high serum hCG results (Table 9). Gener-
ally, an hCG result of > 100,000 is indicative of hydatidi-
form mole [232-234]. In our experience at the USA hCG
Reference Service [49,71] with 30 complete mole cases
pre-evacuation, the median hCG in hydatidiform mole
cases was 192,995 mIU/ml and the range was 24,161 toReproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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3,704,084 mIU/ml (Table 9). Regular hCG is the predom-
inant measurable hCG that is secreted by the villous syn-
cytiotrophoblast tissue. Hyperglycosylated hCG accounts
for 4.9 ± 2.1% of the measured hCG. It is assumed that
this is coming from the extravillous invasive cytotrophob-
last cells on anchoring villi. In 21 partial moles the
median hCG was 48,900 mIU/ml with a range of 11,600
to 220,114 mIU/ml, only 14% of cases exceeded 100,000
mIU/ml. Only 3.6 ± 1.7% of the total hCG of partial
moles were hyperglycosylated hCG. Considering com-
plete and partial mole together, 45% of cases were >
100,000 mIU/ml. The median amount of free β-hCG is
7% and 5% respectively for complete and partial moles,
and likely represents the breakdown product of the high
levels of regular hCG.
The biggest danger with hydatidiform mole is persistence
of disease or invasion by extravillous invasive cytotro-
phoblast cells which can invade the uterus and other
organs. This disease is driven by hyperglycosylated hCG.
Invasive mole is a malignancy comprising differentiated
villous trophoblast cells. Humans uniquely have invasive
gestational trophoblastic diseases. Many physicians con-
sider hysterectomy in women first presenting with hyda-
tidiform mole not interested in having further children.
This avoids all chances of invasive disease. Approximately
29% of complete hydatidiform mole cases [233-238] and
6.6% of partial hydatidiform mole cases [238] will need
treatment for molar invasion. Approximately 3% of com-
plete mole cases and 0.1% of partial mole case will
develop choriocarcinoma or highly malignant invasive
trophoblast disease [239,240]. Invasive mole is marked
by the significant presence of hyperglycosylated hCG
(Table 9). When invasive moles are detected, hyperglyco-
sylated hCG comprises 30 ± 35% of total hCG, making
them distinguishable from non-invasive moles. Generally
[228,229,233-238], an invasive mole is clinically diag-
nosed by one of the following behaviors of regular hCG
measurements: 1) by a plateau in the decline of regular
hCG over three weeks following evacuation of a mole or
2) by an hCG decline that has not fallen below 20,000
mIU/ml over a period on four weeks, or 3) by three rising
weekly hCG values after prior undetectable levels. Detec-
tion of invasive mole dictates the need for single agent
chemotherapy to treat invasive disease. Methotrexate or
actinomycin D are the single agent chemotherapy drugs of
choice.
Choriocarcinoma is a malignancy of transformed non-vil-
lous non-differentiating cytotrophoblast cells (no tro-
phoblastic villous differentiation as observed with
Invasive Mole). The transformation limits cytotrophob-
last differentiation to syncytiotrophoblast cells so that
most cases involve predominantly malignant cytotro-
phoblast cells. The choriocarcinoma cytotrophoblast cells
produce hyperglycosylated hCG which drives growth and
invasion. As much as 100% of the hCG produced in cho-
riocarcinoma can be hyperglycosylated hCG (Table 9)
[18,23,41,49]. Choriocarcinoma commonly is treated by
chemotherapy alone. Without surgery or a biopsy, chistol-
ogy cannot confirm choriocarcinoma. In these cases the
name gestational trophoblastic neoplasm (GTN) is
adopted. Choriocarcinoma can follows a normal preg-
nancy (1 in 20,000 live births) [241], and occurs at a rate
of 1 in 33 complete hydatidiform moles or 1 in 1000 par-
tial moles (1 in 30,000 pregnancies) [237-239]. Chorio-
carcinoma is much more common among Asian people,
tribal people in The Philippines, Indonesia and Central
Africa [229,242]. Choriocarcinoma cases commonly first
present with lung and brain metastasis, with hCG levels
extending to greater than 5,000,0000 mIU/ml [243].
Highly invasive choriocarcinoma is unique and different
from all other hCG producing diseases in that it is marked
by 98 ± 5.0% of hyperglycosylated hCG of total hCG
(Table 9). Most cases are marked by 100% hyperglyco-
sylated hCG. With the production of high concentrations
of hyperglycosylated hCG or invasive signal in choriocar-
cinoma it can be the most aggressive and invasive of all
malignancies, going from no tumor at parturition of preg-
nancy to tumor in the brain, liver and lungs in just 6
weeks. While extremely fast growing it responds exceeding
well to chemotherapy. Five year survival rates for chorio-
carcinoma treated with chemotherapy range from 81% to
91% [243,244]. Multiagent chemotherapy with EMA-CO
(etoposide, methotrexate and actinomycin D oscillating
weekly with cyclophosphamide and onvocin) is the rec-
ommended chemotherapy for choriocarcinoma
[243,244].
Quiescent gestational trophoblastic disease (quiescent
GTD) is a syndrome involving inactive or benign gesta-
tional trophoblastic disease. It comprises solely or pre-
dominantly of highly differentiated syncytiotrophoblast
cells. It has minimal extravillous villous or cancer cell
cytotrophoblast cells so lacks hyperglycosylated hCG the
invasive signal (Table 9). Quiescent GTD was described by
the USA hCG Reference Service in 2002 [245-247], its
existence and tumor marker parameters were later con-
firmed independently in the USA and UK [248,249].
Chemotherapy is ineffective during the quiescent phase
since the cells are very slow growing, it is recommended to
avoid chemotherapy when quiescent GTD is diagnosed
[49].
Quiescent GTD commonly self resolves with the disap-
pearance of hCG over 6 months. The USA hCG Reference
Service knows of 3 cases, however, that perused with no
change in plateau hCG level over 2 years. The USA hCG
Reference Service has consulted on 93 cases of quiescentReproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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GTD (Table 9). In 20 cases (22% of cases) quiescent dis-
ease preceded, however, to active invasive disease. The
majority of these cases occurred in patients previously
treated for choriocarcinoma or GTN. In these cases, rising
hyperglycosylated hCG became evident prior to a signifi-
cant rise in total hCG, which was the first evidence of
active disease [49]. Considering the 22% risk of progres-
sion to active disease, it is critical to monitor hCG regu-
larly in quiescent GTD cases. We recommend that woman
with quiescent GTD be placed on an oral contraceptive
pill and avoid achieving pregnancy, at least until hCG has
been undetectable for 6 months.
Many of the cases referred to the USA hCG Reference Serv-
ice were inadvertently given chemotherapy for assumed
invasive mole or persistent disease. Half of the 101 cases
received needless chemotherapy, multiple regimens of
chemotherapy or hysterectomy for assumed active dis-
ease. We know of no case in which the therapy appropri-
ately suppressed disease (hCG < 1 mIU/L). The failure of
chemotherapy to eradicate hCG producing trophoblasts is
likely because of the lack of proliferation of the inactive
quiescent disease. We know of one patient who died due
to complications of the chemotherapy regimens. We con-
clude that chemotherapy and surgery should be avoided
in cases of quiescent GTD. We also infer that it is impor-
tant to consider quiescent GTD when a mole, GTN or cho-
riocarcinoma case demonstrates an hCG plateau below
215 mIU/ml before commencing chemotherapy. If a
hyperglycosylated hCG test is not available, then the per-
sistence of total hCG results, permitting a 2 fold natural
variation, should be monitored and considered as evi-
dence for inactive or static disease. It should noted that <
212 mIU/ml represents a miniscule trophoblast cell mass,
and that > 2,000 mIU/ml of hCG in serum is required
before a tumor could be seen by MRI [240].
Hyperglycosylated hCG free β immunoassays and 
placental site trophoblastic tumor (PSTT)
PSTT is a malignancy of of so called intermediate trophob-
last cells, syncytiotrophoblast cells with 3–5 nuclei). As
such, it does not produce hyperglycosylated hCG. It is a
very rare condition accounting for 1 in approximately
40,000 pregnancies. It also has a poorer prognosis than
choriocarcinoma [250,251]. The five year survival rate for
PSTT is 74% [250], compared with 91% for choriocarci-
noma [244]. Classically it presents as a tumor in the
uterus, which is readily removed by hysterectomy.
The range of regular hCG in PSTT cases, if present, varies
substantially, reportedly between 6 to 107,000 mIU/ml.
The USA hCG Reference Service has consulted on 7 PSTT
histology-proven cases. It was noted that all primarily pro-
duced hyperglycosylated hCG free β-subunit rather than
regular hCG or hyperglycosylated hCG, even though these
tumors involve syncytiotrophoblast cells. As discussed in
this review article, hyperglycosylated hCG free β acts like
hyperglycosylated hCG as a promoter of cancer cell
growth and invasion. It was suggested by the USA hCG
Reference Service that the proportion of hyperglyco-
sylated hCG free β (> 30% of total hCG) may be an abso-
lute marker for discriminating choriocarcinoma and PSTT
[252]. Since this time the USA hCG Reference Service has
used an hCG free β tests to show that 14 further cases were
PSTT and not choriocarcinoma [253,254]. This was later
confirmed by expert pathology un the month that follow.
Reviewing all 21 cases referred to the USA hCG Reference
Service to date, the median regular hCG was 30 mIU/ml
(range 1 – 231 mIU/ml). The proportion of hCG free β
averaged 61% of the total hCG concentration (Table 9).
PSTT requires a very different treatment protocol to GTN
and choriocarcinoma. As such, it is important to make
sure that the diagnosis is correct. The hCG free β subunit
tests is widely available at clinical laboratories for Down
syndrome screening (results presented as multiple of
median). Special arrangements will need to be made with
laboratory to obtain a concentration for cancer assess-
ment. Results are normally determined in nanograms per
milliliter. One nanogram per milliliter is equivalent to 18
mIU/ml.
Hyperglycosylated hCG free β immunoassays and cancer
It has long been known that most non-trophoblastic
malignancies in advanced stages produce the hyperglyco-
sylated hCG free β. Early reports note free β production by
cervical cancer, breast, bladder, ovarian, brain, colorectal,
uterine, brain and lung malignancy cell lines [30,122,255-
261]. As reported by Acevedo et al. [58] and by Regelson
[28], almost every human malignancy generates hypergly-
cosylated hCG free β. This claims is somewhat debatable,
and at best the diagnostic potential for even the most rec-
ognised free β producing tumors is around 38% (Table
10). However, more recent studies clearly show that while
the hyperglycosylated hCG free β is not a reliable diagnos-
tic marker or a good marker in these non-trophoblastic
malignancies it does have value as an excellent marker for
poor prognosis (24). Hyperglycosylated hCG free is termi-
nally degraded to generate β-subunit core fragment, β6–
40 disulfide linked to β55–92, with degraded oligosaccha-
rides(Figure 3), a more sensitive tumor marker in urine
samples (Table 11) [32,262]. Serum hyperglycosylated
hCG free β and urine β-subunit core fragment have both
proven useful in the detection and management of a wide
range of malignancies [32,256,262,263,265-270]. As
shown in Tables 10 and 11, 47% of 558 malignancy cases
tested for urine β-subunit core fragment and 30% of 1202
malignancy cases tested for serum free β were positive. The
expression of the free β or detection of β-subunit core frag-
ment in a patient with malignancy correlates with poorReproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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grade and stage of tumor [31,59], indicating that expres-
sion of free β is associated with a negative outcome in
human malignancies.
Examining Tables 10 and 11, with few exceptions, gyneco-
logic and urinary tract malignancies appear to be the big-
gest producers of free β. Free β is detected in serum in 38%
of ovarian malignancies and β-subunit core fragment in
the urine of 68% of malignancies. Similarly, free β is
detected in the serum of 38% of bladder malignancies and
β-subunit core fragment in the urine of 48% of malignan-
cies. In contrast, free β is detected in the serum of just 18%
of lung cancer cases and β-subunit core fragment in the
urine of just 24% of malignancies. Serum free β and urine
β-core fragment are very non specific markers, detecting a
proportion of all malignancies. The urine β-core fragment
test may be useful as a general screening test for malignan-
cies used at annual physical examination or in a life insur-
ance examination detecting 47% of malignancies. A
positive test, however, would need to be followed by a
complete body malignancy scan (MRI scan of head and
pelvis and CT scan of chest) to detect the malignancy.
We question why non-gestational malignancies produce
hyperglycosylated hCG free β while choriocarcinoma
makes the hyperglycosylated hCG dimer? Research indi-
cates that in general, hCG dimer is associated with high β-
subunit production, 1 mIU/ml to > 5,000,000 mIU/ml
dimer in blood, observed in trophoblastic neoplasms and
choriocarcinoma, while hyperglycosylated hCG free β is
associated with low β-subunit production, 1 – 200 mIU/
ml in blood, by non-trophoblastic malignancies
[49,31,252]. This is consistent with concentration and the
law of mass action. In contrast, during very early preg-
nancy, and in quiescent and recurrent choriocarcinoma
and gestational trophoblastic neoplasms, low concentra-
tions (0.1 – 20 ng/ml) of dimer alone may be produced
[43,49]. This argues against the law of mass action being
the cause of free subunit productions, and suggests that
trophoblast cells may simply be much better equipped for
producing α – and β-subunits held as dimer when com-
pared with non-trophoblastic neoplasm cells.
Conclusion
The field of hCG has changed dramatically in the past 10
years. This is the focus of this review. It has moved from
hCG a hormone produced by trophoblast cells that pro-
motes progesterone production by luteal cells to hCG as
group of molecules each with different functions. That is
regular hCG a hormone produced by syncytiotrophoblast
cells which promotes myometrial spiral artery angiogen-
esis, aiding nutrient supply to the placenta. Hyperglyco-
sylated hCG is an autocrine factor made by extrauterine
invasive cytotrophoblast cells in pregnancy and malig-
nant cell non-villous cytotrophoblast cell is choriocarci-
noma and testicular germ cell malignancies. This form of
hCG controls placental invasion and implantation and
cancer cell malignancy. Hyperglycosylated hCG free β is
an invasion promoter made by non-trophoblastic cancer
cells which enhances cancer cell growth and malignancy.
All of these new findings have been confirmed by multi-
ple separate laboratories. In many ways, the new hCG as
we know it today, is a very unique molecule, one α and
one β polypeptide structure and 3 independent bioactive
molecules. This is a unique biological combination, 3
molecules differing in carbohydrate structure.
Major changes have also occurred in the past 10 years in
the hCG immunoassay field, New perspectives on hCG
assays and what they should detect. Multiple new applica-
tion for hyperglycosylated hCG in Down syndrome
screening, detecting pregnancy, detecting pregnancy fail-
ures and in the diagnosis and management of gestational
trophoblastic diseases. New applications for free β in pre-
dicting Down syndrome pregnancies, in diagnoses of
PSTT and as a tumor marker for all non-gestational malig-
nancies, and new vaccine treatments blocking free β
enhancing survival of malignancies.
Table 10: Use of serum free β-subunit as a tumor marker for 
detection of malignancies.
Malignancy Patients Sensitivity (> 3 fmol/ml)
Ovarian cancer 150 38% average of 3 reports
Cervical cancer 60 37% average of 2 reports
Endometrial cancer 55 33% average of 2 reports
Vulvar 50 38% single report
Bladder cancer 99 38% average of 2 reports
Lung cancer 177 18% average of 2 reports
Colorectal cancer 436 17% average of 2 reports
TOTAL 1152 30% average of 16 reports
Averages are determined from multiple reports by combining total 
cases positive for free β-subunit by total cases tested.
Table 11: Use of urine β-subunit core fragment as a tumor 
marker for detection of malignancies.
Malignancy Patients Sensitivity (> 3 fmol/ml)
Healthy no history of malignancy 97 9.3%
Healthy benign disease 159 6.9%
TOTAL 256 7.8%
Ovarian cancer 106 68%
Cervical cancer 89 46%
Endometrial cancer 110 51%
Pancreatic cancer 29 55%
Bladder cancer 102 48%
Lung cancer 122 24%
TOTAL 558 47%Reproductive Biology and Endocrinology 2009, 7:8 http://www.rbej.com/content/7/1/8
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In many respects the new discoveries are like the rediscov-
ery of hCG as a group of molecules has occurred, a group
of molecules critical to human evolution and essential to
human pregnancy. With all the new doors opening in the
hCG story, everything is still far from complete. Yes, we
know that hyperglycosylated hCG is an autocrine factor
that controls extravillous invasive cytotrophoblast growth
and invasion but we are far from sure what receptor it
binds. We know that its mechanism involves blocking
apoptosis, but how does it promote metalloproteinases to
advance invasion? Multiple indications and preliminary
studies suggest a TGFβ-like receptor but this is far from
proven. This needs to be resolved. Similarly, we know that
hyperglycosylated hCG free β also seemingly binds a
cytokine receptor and works through a mechanism
involving antagonism of apoptosis, but what receptor
does this bind? This also needs to be resolved. The idea
evolves of using hyperglycosylated hCG to prevent failure
of pregnancy and to prevent preeclampsia. It sounds
incredible to consider preventing these complications of
pregnancy, but at least ten years of testing in advanced pri-
mate and human clinical trials is needed before this can
become realistic. Clinical trials are already ongoing using
in hCG β-subunit vaccine in the treatment of malignan-
cies. A lot of promise is in store. At the current time we do
not have a standard for hyperglycosylated hCG or com-
mercial or recombinant method for producing hyperglyc-
osylated hCG, maybe this is a first step. A lot of
improvement is needed in the coming years in hCG assay
development, in improving total hCG assays to measure
regular hCG, hyperglycosylated hCG and hyperglyco-
sylated hCG free β on an equi-molar basis, and in the
development of new hyperglycosylated hCG only assays,
using them in IVF pregnancy testing and applying them to
pregnancy failures and other promising applications. Yes,
the past 10 years has shown great advances in the field of
hCG, what the next 10 years may show could be even
more exciting.
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